U.S. patent application number 14/893785 was filed with the patent office on 2016-04-14 for fungicidal compositions.
The applicant listed for this patent is VIAMET PHARMACEUTICALS, INC.. Invention is credited to Zachary A. Buchan, Gary D. Gustafson, William Hoekstra, Daniel Knueppel, Michael R. Loso, Michael T. Sullenberger.
Application Number | 20160102072 14/893785 |
Document ID | / |
Family ID | 51989367 |
Filed Date | 2016-04-14 |
United States Patent
Application |
20160102072 |
Kind Code |
A1 |
Hoekstra; William ; et
al. |
April 14, 2016 |
FUNGICIDAL COMPOSITIONS
Abstract
The instant invention describes tetrazole compounds having
metalloenzyme modulating activity, and methods of treating
diseases, disorders or symptoms thereof mediated by such
metalloenzymes.
Inventors: |
Hoekstra; William; (Durham,
NC) ; Loso; Michael R.; (Carmel, IN) ;
Gustafson; Gary D.; (Zionsville, IN) ; Knueppel;
Daniel; (Zionsville, IN) ; Buchan; Zachary A.;
(Indianpolis, IN) ; Sullenberger; Michael T.;
(Westfield, IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
VIAMET PHARMACEUTICALS, INC. |
Durham |
NC |
US |
|
|
Family ID: |
51989367 |
Appl. No.: |
14/893785 |
Filed: |
May 28, 2014 |
PCT Filed: |
May 28, 2014 |
PCT NO: |
PCT/US2014/039823 |
371 Date: |
November 24, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61828068 |
May 28, 2013 |
|
|
|
Current U.S.
Class: |
514/340 ;
435/184; 546/268.4 |
Current CPC
Class: |
A61P 29/00 20180101;
A61P 9/00 20180101; A61P 35/00 20180101; A61P 15/00 20180101; A61P
1/04 20180101; A01N 43/713 20130101; A61P 25/00 20180101; A61P 5/00
20180101; C07D 257/04 20130101; A61P 31/10 20180101; C07D 401/14
20130101; C07D 401/06 20130101; A61P 17/00 20180101; A61P 3/00
20180101; A61P 43/00 20180101; A61P 31/00 20180101; A61P 13/00
20180101; A61P 27/02 20180101 |
International
Class: |
C07D 401/06 20060101
C07D401/06; A01N 43/713 20060101 A01N043/713 |
Claims
1. A compound of Formula I, or salt, solvate, hydrate or prodrug
thereof, wherein: ##STR00054## MBG is ##STR00055## R.sub.1 is H,
alkyl, haloalkyl, cycloalkyl, benzyl, or (heteroaryl)alkyl; R.sub.2
is halo, aryl, heteroaryl, aryloxy, alkoxy, haloalkoxy,
heteoaryloxy, alkyl, cycloalkyl, cycloalkoxy, halocycloalkoxy,
haloalkyl, (alkoxy)alkyl, (haloalkoxy)alkyl, (aryl)alkyl,
(aryl)alkenyl, (aryl)alkynyl, or (heteroaryl)alkyl wherein each of
the aryls and heteroaryls can independently be substituted with 1,
2 or 3 groups from R.sub.4; R.sub.3 is aryl, heteroaryl, alkyl or
cycloalkyl optionally substituted with 0, 1, 2 or 3 independent
R.sub.4; and R.sub.4 is independently halo, alkyl, haloalkyl,
thioalkyl, thiohaloalkyl, NO.sub.2, CN, alkoxy, haloalkoxy, or
thioamide ((C.dbd.S)NH.sub.2).
2. A compound of claim 1 wherein R.sub.1 is H, benzyl or alkyl.
3. A compound of claim 2 wherein R.sub.1 is H.
4. A compound of claim 1 wherein R.sub.2 is aryloxy, heteoaryloxy,
alkyl, cycloalkyl, haloalkyl, (alkoxy)alkyl, (haloalkoxy)alkyl,
alkoxy, haloalkoxy or halocycloalkoxy wherein each of the aryls and
heteroaryls can independently be substituted with 1, 2 or 3 groups
from R.sub.4.
5. A compound of claim 1 wherein R.sub.3 is phenyl optionally
substituted with 0, 1, 2 or 3 independent halo.
6. A compound of claim 5 wherein R.sub.3 is 2,4-difluorophenyl or
2-fluoro-4-chlorophenyl.
7. A compound of claim 1 wherein R.sub.4 is independently F, Cl,
Br, CF.sub.3, OCF.sub.3, CN or thioamide ((C.dbd.S)NH.sub.2).
8. A compound of claim 1 wherein: R.sub.1 is H, benzyl or alkyl;
R.sub.2 is aryloxy, heteoaryloxy, alkyl, cycloalkyl, haloalkyl,
(alkoxy)alkyl, (haloalkoxy)alkyl, alkoxy, haloalkoxy or
halocycloalkoxy wherein each of the aryls and heteroaryls can
independently be substituted with 1, 2 or 3 groups from R.sub.4;
R.sub.3 is phenyl optionally substituted with 0, 1, 2 or 3
independent halo; and R.sub.4 is independently F, Cl, Br, CF.sub.3,
OCF.sub.3, CN or thioamide ((C.dbd.S)NH.sub.2).
9.-20. (canceled)
21. A method of inhibiting metalloenzyme activity comprising
contacting a compound of claim 1 with a metalloenzyme.
22. The method of claim 21, wherein the contacting is in vivo.
23. The method of claim 21, wherein the contacting is in vitro.
24.-38. (canceled)
39. A composition comprising a compound of claim 1 and an
agriculturally acceptable carrier.
40. A method of treating or preventing a metalloenzyme-mediated
disease or disorder in or on a plant comprising contacting a
compound of claim 1 with the plant or seeds.
41. (canceled)
42. A method of treating or preventing a fungal disease or disorder
in or on a plant comprising contacting a compound of claim 1 with
the plant or seeds.
43. A method of treating or preventing fungal growth in or on a
plant comprising contacting a compound of claim 1 with the plant or
seeds.
44. (canceled)
45. The composition according to claim 39, further comprising an
azole fungicide selected from epoxyconazole, tebuconazole,
fluquinconazole, flutriafol, metconazole, myclobutanil,
cycproconazole, prothioconazole and propiconazole.
46. The composition according to claim 39, further comprising a
strobilurin fungicide from the group trifloxystrobin,
pyraclostrobin, orysastrobin, fluoxastrobin and azoxystrobin.
47.-49. (canceled)
50. A compound of Formula II wherein: ##STR00056## R.sub.5 is halo,
aryl, heteroaryl, aryloxy, alkoxy, haloalkoxy, heteoaryloxy, alkyl,
cycloalkyl, cycloalkoxy, halocycloalkoxy, haloalkyl, (alkoxy)alkyl,
(haloalkoxy)alkyl, (aryl)alkyl, (aryl)alkenyl, (aryl)alkynyl, or
(heteroaryl)alkyl wherein each of the aryls and heteroaryls can
independently be substituted with 1, 2 or 3 groups from R.sub.6;
and R.sub.6 is independently halo, alkyl, haloalkyl, thioalkyl,
thiohaloalkyl, NO.sub.2, CN, alkoxy, haloalkoxy, or thioamide
((C.dbd.S)NH.sub.2); with the proviso that R.sub.5 cannot be
##STR00057##
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U.S.
Provisional Patent Application No: 61/828,068 filed May 28, 2013,
the contents of which are incorporated herein by reference.
BACKGROUND
[0002] Living organisms have developed tightly regulated processes
that specifically import metals, transport them to intracellular
storage sites and ultimately transport them to sites of use. One of
the most important functions of metals such as zinc and iron in
biological systems is to enable the activity of metalloenzymes.
Metalloenzymes are enzymes that incorporate metal ions into the
enzyme active site and utilize the metal as a part of the catalytic
process. More than one-third of all characterized enzymes are
metalloenzymes.
[0003] The function of metalloenzymes is highly dependent on the
presence of the metal ion in the active site of the enzyme. It is
well recognized that agents which bind to and inactivate the active
site metal ion dramatically decrease the activity of the enzyme.
Nature employs this same strategy to decrease the activity of
certain metalloenzymes during periods in which the enzymatic
activity is undesirable. For example, the protein TIMP (tissue
inhibitor of metalloproteases) binds to the zinc ion in the active
site of various matrix metalloprotease enzymes and thereby arrests
the enzymatic activity. The pharmaceutical industry has used the
same strategy in the design of therapeutic agents. For example, the
azole antifungal agents fluconazole and voriconazole contain a
1-(1,2,4-triazole) group that binds to the heme iron present in the
active site of the target enzyme lanosterol demethylase and thereby
inactivates the enzyme. Another example includes the zinc-binding
hydroxamic acid group that has been incorporated into most
published inhibitors of matrix metalloproteinases and histone
deacetylases. Another example is the zinc-binding carboxylic acid
group that has been incorporated into most published
angiotensin-converting enzyme inhibitors.
[0004] In the design of clinically safe and effective metalloenzyme
inhibitors, use of the most appropriate metal-binding group for the
particular target and clinical indication is critical. If a weakly
binding metal-binding group is utilized, potency may be suboptimal.
On the other hand, if a very tightly binding metal-binding group is
utilized, selectivity for the target enzyme versus related
metalloenzymes may be suboptimal. The lack of optimal selectivity
can be a cause for clinical toxicity due to unintended inhibition
of these off-target metalloenzymes. One example of such clinical
toxicity is the unintended inhibition of human drug metabolizing
enzymes such as cytochrome P450 2C9 (CYP2C9), CYP2C19 and CYP3A4 by
the currently-available azole antifungal agents such as fluconazole
and voriconazole. It is believed that this off-target inhibition is
caused primarily by the indiscriminate binding of the currently
utilized 1-(1,2,4-triazole) to iron in the active site of CYP2C9,
CYP2C19 and CYP3A4. Another example of this is the joint pain that
has been observed in many clinical trials of matrix
metalloproteinase inhibitors. This toxicity is considered to be
related to inhibition of off-target metalloenzymes due to
indiscriminate binding of the hydroxamic acid group to zinc in the
off-target active sites.
[0005] Therefore, the search for metal-binding groups that can
achieve a better balance of potency and selectivity remains an
important goal and would be significant in the realization of
therapeutic agents and methods to address currently unmet needs in
treating and preventing diseases, disorders and symptoms
thereof.
[0006] Fungicides are compounds, of natural or synthetic origin,
which act to protect and cure plants against damage caused by
agriculturally relevant fungi. Generally, no single fungicide is
useful in all situations. Consequently, research is ongoing to
produce fungicides that may have better performance, are easier to
use, and cost less.
[0007] The present disclosure relates to compounds of Formula I,
shown below, and their derivatives and their use as fungicides. The
compounds of the present disclosure may offer protection against
ascomycetes, basidiomycetes, deuteromycetes and oomycetes.
BRIEF SUMMARY OF THE INVENTION
[0008] The invention is directed towards compounds (e.g., any of
those delineated herein), methods of modulating activity of
metalloenzymes, and methods of treating diseases, disorders or
symptoms thereof. The methods can comprise the compounds
herein.
[0009] A method of controlling a pathogen-induced disease in a
plant that is at risk of being diseased from the pathogen
comprising contacting one of the plant and an area adjacent to the
plant with a composition of Formula I, or salt, solvate, hydrate or
prodrug thereof, wherein:
##STR00001##
[0010] MBG is
##STR00002##
[0011] R.sub.1 is H, alkyl, haloalkyl, cycloalkyl, benzyl, or
(heteroaryl)alkyl;
[0012] R.sub.2 is halo, aryl, heteroaryl, aryloxy, alkoxy,
haloalkoxy, heteoaryloxy, alkyl, cycloalkyl, cycloalkoxy,
halocycloalkoxy, haloalkyl, (alkoxy)alkyl, (haloalkoxy)alkyl,
(aryl)alkyl, (aryl)alkenyl, (aryl)alkynyl, or (heteroaryl)alkyl
wherein each of the aryls and heteroaryls can independently be
substituted with 1-3 groups from R.sub.4;
[0013] R.sub.3 is aryl, heteroaryl, alkyl or cycloalkyl optionally
substituted with 0, 1, 2 or 3 independent R.sub.4; and
[0014] R.sub.4 is independently halo, alkyl, haloalkyl, thioalkyl,
thiohaloalkyl, NO.sub.2, CN, alkoxy, haloalkoxy, or thioamide
((C.dbd.S)NH.sub.2).
[0015] Other aspects are a compound of any of the formulae herein,
wherein:
[0016] R.sub.1 is H, benzyl or alkyl;
[0017] R.sub.1 is H;
[0018] R.sub.2 is aryloxy, heteoaryloxy, alkyl, cycloalkyl,
haloalkyl, (alkoxy)alkyl, (haloalkoxy)alkyl, alkoxy, haloalkoxy or
halocycloalkoxy wherein each of the aryls and heteroaryls can
independently be substituted with 1-3 groups from R.sub.4;
[0019] R.sub.3 is phenyl optionally substituted with 0, 1, 2 or 3
independent halo;
[0020] R.sub.3 is 2,4-difluorophenyl or 2-fluoro-4-chlorophenyl;
and R.sub.4 is independently F, Cl, Br, CF.sub.3, OCF.sub.3, CN or
thioamide ((C.dbd.S)NH.sub.2).
[0021] The compounds herein include those wherein the compound is
identified as attaining affinity, at least in part, for a
metalloenzyme by formation of one or more of the following types of
chemical interactions or bonds to a metal: sigma bonds, covalent
bonds, coordinate-covalent bonds, ionic bonds, pi bonds, delta
bonds, or backbonding interactions. The compounds can also attain
affinity through weaker interactions with the metal such as van der
Waals interactions, pi cation interactions, pi-anion interactions,
dipole-dipole interactions, ion-dipole interactions. In one aspect,
the compound is identified as having a bonding interaction with the
metal via the 1-tetrazolyl moiety; in another aspect, the compound
is identified as having a bonding interaction with the metal via
the N2 of the 1-tetrazolyl moiety; in another aspect, the compound
is identified as having a bonding interaction with the metal via
the N3 of the 1-tetrazolyl moiety; in another aspect, the compound
is identified as having a bonding interaction with the metal via
the N4 of the 1-tetrazolyl moiety.
[0022] Methods for assessing metal-ligand binding interactions are
known in the art as exemplified in references including, for
example, "Principles of Bioinorganic Chemistry" by Lippard and
Berg, University Science Books, (1994); "Mechanisms of Inorganic
Reactions" by Basolo and Pearson, John Wiley & Sons Inc; 2nd
edition (September 1967); "Biological Inorganic Chemistry" by Ivano
Bertini, Harry Gray, Ed Stiefel, Joan Valentine, University Science
Books (2007); Xue et al. "Nature Chemical Biology", vol. 4, no. 2,
107-109 (2008).
[0023] In another aspect, the invention provides an agricultural
composition comprising the compound of Formula I and an
agriculturally acceptable carrier.
[0024] In other aspects, the invention provides a compound of any
of the formulae herein, wherein the compound inhibits (or is
identified to inhibit) lanosterol demethylase (CYP51).
[0025] In other aspects, the invention provides a compound of any
of the formulae herein, wherein the compound is identified as
having an activity range against a target enzyme and an activity
range against an off-target enzyme (e.g., C. albicans minimum
inhibitory concentration (MIC)<0.25 micrograms per milliliter
(.mu.g/mL) and half maximal inhibitory concentration
(IC.sub.50)>8 micromolar (.mu.M) for CYP2C9, CYP2C19 and
CYP3A4).
[0026] In another aspect, the invention provides a pharmaceutical
composition comprising the compound of Formula I and a
pharmaceutically acceptable carrier.
[0027] In other aspects, the invention provides a method of
modulating metalloenzyme activity in a subject, comprising
contacting the subject with a compound of any of the formulae
herein (e.g., Formula I), in an amount and under conditions
sufficient to modulate metalloenzyme activity.
[0028] In one aspect, the invention provides a method of treating a
subject suffering from or susceptible to a metalloenzyme-related
disorder or disease, comprising administering to the subject an
effective amount of a compound any of the formulae herein (e.g.,
Formula I), or pharmaceutical composition thereof.
[0029] In another aspect, the invention provides a method of
treating a subject suffering from or susceptible to a
metalloenzyme-related disorder or disease, wherein the subject has
been identified as in need of treatment for a metalloenzyme-related
disorder or disease, comprising administering to said subject in
need thereof, an effective amount of a compound any of the formulae
herein (e.g., Formula I), or pharmaceutical composition thereof,
such that said subject is treated for said disorder.
[0030] In another aspect, the invention provides a method of
treating a subject suffering from or susceptible to a
metalloenzyme-mediated disorder or disease, wherein the subject has
been identified as in need of treatment for a
metalloenzyme-mediated disorder or disease, comprising
administering to said subject in need thereof, an effective amount
of a compound any of the formulae herein (e.g., Formula I), or
pharmaceutical composition thereof, such that metalloenzyme
activity in said subject is modulated (e.g., down regulated,
inhibited).
[0031] The methods herein include those wherein the disease or
disorder is mediated by any of 4-hydroxyphenyl pyruvate
dioxygenase, 5-lipoxygenase, adenosine deaminase, alcohol
dehydrogenase, aminopeptidase N, angiotensin converting enzyme,
aromatase (CYP19), calcineurin, carbamoyl phosphate synthetase,
carbonic anhydrase family, catechol-O-methyl transferase,
cyclooxygenase family, dihydropyrimidine dehydrogenase-1, DNA
polymerase, farnesyl diphosphate synthase, farnesyl transferase,
fumarate reductase, GABA aminotransferase, HIF-prolyl hydroxylase,
histone deacetylase family, HIV integrase, HIV-1 reverse
transcriptase, isoleucine tRNA ligase, lanosterol demethylase
(CYP51), matrix metalloprotease family, methionine aminopeptidase,
neutral endopeptidase, nitric oxide synthase family,
phosphodiesterase III, phosphodiesteraseIV, phosphodiesteraseV,
pyruvate ferredoxin oxidoreductase, renal peptidase, ribonucleoside
diphosphate reductase, thromboxane synthase (CYP5a), thyroid
peroxidase, tyrosinase, urease, or xanthine oxidase.
[0032] The methods herein include those wherein the disease or
disorder is mediated by any of 1-deoxy-D-xylulose-5-phosphate
reductoisomerase (DXR), 17-alpha hydroxylase (CYP17), aldosterone
synthase (CYP11B2), aminopeptidase P, anthrax lethal factor,
arginase, beta-lactamase, cytochrome P450 2A6, D-Ala D-Ala ligase,
dopamine beta-hydroxylase, endothelin converting enzyme-1,
glutamate carboxypeptidase II, glutaminyl cyclase, glyoxalase, heme
oxygenase, HPV/HSV E1 helicase, indoleamine 2,3-dioxygenase,
leukotriene A4 hydrolase, methionine aminopeptidase 2, peptide
deformylase, phosphodiesteraseVII, relaxase, retinoic acid
hydroxylase (CYP26), TNF-alpha converting enzyme (TACE),
UDP-(3-O--(R-3-hydroxymyristoyl))-N-acetylglucosamine deacetylase
(LpxC), vascular adhesion protein-1 (VAP-1), or vitamin D
hydroxylase (CYP24).
[0033] The methods herein include those wherein the disease or
disorder is cancer, cardiovascular disease, inflammatory disease,
infectious disease, metabolic disease, ophthalmologic disease,
central nervous system (CNS) disease, urologic disease, or
gastrointestinal disease.
[0034] The methods herein include those wherein the disease or
disorder is prostate cancer, breast cancer, inflammatory bowel
disease, psoriasis, systemic fungal infection, skin structure
fungal infection, mucosal fungal infection, or onychomycosis.
[0035] Methods delineated herein include those wherein the subject
is identified as in need of a particular stated treatment.
Identifying a subject in need of such treatment can be in the
judgment of a subject or a health care professional and can be
subjective (e.g. opinion) or objective (e.g. measurable by a test
or diagnostic method).
[0036] Another aspect of the invention is a composition comprising
a compound of a formulae herein (e.g., Formula I) and an
agriculturally acceptable carrier.
[0037] Another aspect of the invention is a method of treating or
preventing a metalloenzyme-mediated disease or disorder in or on a
plant comprising contacting a compound herein with the plant.
[0038] Another aspect of the invention is a method of inhibiting
metalloenzyme activity in or on a plant comprising contacting a
compound herein with the plant.
DETAILED DESCRIPTION
Definitions
[0039] In order that the invention may be more readily understood,
certain terms are first defined here for convenience.
[0040] As used herein, the term "treating" a disorder encompasses
preventing, ameliorating, mitigating and/or managing the disorder
and/or conditions that may cause the disorder. The terms "treating"
and "treatment" refer to a method of alleviating or abating a
disease and/or its attendant symptoms. In accordance with the
present invention "treating" includes preventing, blocking,
inhibiting, attenuating, protecting against, modulating, reversing
the effects of and reducing the occurrence of e.g., the harmful
effects of a disorder.
[0041] As used herein, "inhibiting" encompasses preventing,
reducing and halting progression. Note that "enzyme inhibition"
(e.g., metalloenzyme inhibition) is distinguished and described
below.
[0042] The term "modulate" refers to increases or decreases in the
activity of an enzyme in response to exposure to a compound of the
invention.
[0043] The terms "isolated," "purified," or "biologically pure"
refer to material that is substantially or essentially free from
components that normally accompany it as found in its native state.
Purity and homogeneity are typically determined using analytical
chemistry techniques such as polyacrylamide gel electrophoresis or
high performance liquid chromatography. Particularly, in
embodiments the compound is at least 85% pure, more preferably at
least 90% pure, more preferably at least 95% pure, and most
preferably at least 99% pure.
[0044] The term "administration" or "administering" includes routes
of introducing the compound(s) to a subject to perform their
intended function. Examples of routes of administration which can
be used include injection (subcutaneous, intravenous, parenterally,
intraperitoneally, intrathecal), topical, oral, inhalation, rectal
and transdermal.
[0045] The term "effective amount" includes an amount effective, at
dosages and for periods of time necessary, to achieve the desired
result. An effective amount of compound may vary according to
factors such as the disease state, age, and weight of the subject,
and the ability of the compound to elicit a desired response in the
subject. Dosage regimens may be adjusted to provide the optimum
therapeutic response. An effective amount is also one in which any
toxic or detrimental effects (e.g., side effects) of the inhibitor
compound are outweighed by the therapeutically beneficial
effects.
[0046] The phrases "systemic administration," "administered
systemically", "peripheral administration" and "administered
peripherally" as used herein mean the administration of a
compound(s), drug or other material, such that it enters the
patient's system and, thus, is subject to metabolism and other like
processes.
[0047] The term "therapeutically or agriculturally effective
amount" refers to that amount of the compound being administered
sufficient to prevent development of or alleviate to some extent
one or more of the symptoms of the condition or disorder being
treated.
[0048] A therapeutically effective amount of compound (i.e., an
effective dosage) may range from about 0.005 micrograms per
kilogram (.mu.g/kg) to about 200 milligrams per kilogram (mg/kg),
preferably about 0.01 mg/kg to about 200 mg/kg, more preferably
about 0.015 mg/kg to about 30 mg/kg of body weight. In other
embodiments, the therapeutically effect amount may range from about
1.0 picomolar (pM) to about 10 .mu.M. The skilled artisan will
appreciate that certain factors may influence the dosage required
to effectively treat a subject, including but not limited to the
severity of the disease or disorder, previous treatments, the
general health and/or age of the subject, and other diseases
present. Moreover, treatment of a subject with a therapeutically
effective amount of a compound can include a single treatment or,
preferably, can include a series of treatments. In one example, a
subject is treated with a compound in the range of between about
0.005 .mu.g/kg to about 200 mg/kg of body weight, one time per day
for between about 1 to 10 weeks, preferably between about 2 to 8
weeks, more preferably between about 3 to 7 weeks, and even more
preferably for about 4, 5, or 6 weeks. In another example, a
subject may be treated daily for several years in the setting of a
chronic condition or illness. It will also be appreciated that the
effective dosage of a compound used for treatment may increase or
decrease over the course of a particular treatment.
[0049] The term "chiral" refers to molecules which have the
property of non-superimposability of the mirror image partner,
while the term "achiral" refers to molecules which are
superimposable on their mirror image partner.
[0050] The term "diastereomers" refers to stereoisomers with two or
more centers of dissymmetry and whose molecules are not mirror
images of one another.
[0051] The term "enantiomers" refers to two stereoisomers of a
compound which are non-superimposable mirror images of one another.
An equimolar mixture of two enantiomers is called a "racemic
mixture" or a "racemate."
[0052] The term "isomers" or "stereoisomers" refers to compounds
which have identical chemical constitution, but differ with regard
to the arrangement of the atoms or groups in space.
[0053] The term "prodrug" includes compounds with moieties which
can be metabolized in vivo. Generally, the prodrugs are metabolized
in vivo by esterases or by other mechanisms to active drugs.
Examples of prodrugs and their uses are well known in the art (See,
e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci.
66:1-19). The prodrugs can be prepared in situ during the final
isolation and purification of the compounds, or by separately
reacting the purified compound in its free acid form or hydroxyl
with a suitable esterifying agent. Hydroxyl groups can be converted
into esters via treatment with a carboxylic acid. Examples of
prodrug moieties include substituted and unsubstituted, branched or
unbranched lower alkyl ester moieties, (e.g., propionic acid
esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl
esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl
esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters
(e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester),
aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g.,
with methyl, halo, or methoxy substituents) aryl and aryl-lower
alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides,
and hydroxy amides. Preferred prodrug moieties are propionoic acid
esters and acyl esters. Prodrugs which are converted to active
forms through other mechanisms in vivo are also included. In
aspects, the compounds of the invention are prodrugs of any of the
formulae herein.
[0054] The term "subject" refers to animals such as mammals,
including, but not limited to, primates (e.g., humans), cows,
sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like.
In certain embodiments, the subject is a human.
[0055] The terms "a," "an," and "the" refer to "one or more" when
used in this application, including the claims. Thus, for example,
reference to "a sample" includes a plurality of samples, unless the
context clearly is to the contrary (e.g., a plurality of samples),
and so forth.
[0056] Throughout this specification and the claims, the words
"comprise," "comprises," and "comprising" are used in a
non-exclusive sense, except where the context requires
otherwise.
[0057] As used herein, the term "about," when referring to a value
is meant to encompass variations of, in some embodiments .+-.20%,
in some embodiments .+-.10%, in some embodiments .+-.5%, in some
embodiments .+-.1%, in some embodiments .+-.0.5%, and in some
embodiments .+-.0.1% from the specified amount, as such variations
are appropriate to perform the disclosed methods or employ the
disclosed compositions.
[0058] Use of the word "inhibitor" herein is meant to mean a
molecule that exhibits activity for inhibiting a metalloenzyme. By
"inhibit" herein is meant to decrease the activity of a
metalloenzyme, as compared to the activity of a metalloenzyme in
the absence of the inhibitor. In some embodiments, the term
"inhibit" means a decrease in metalloenzyme activity of at least
about 5%, at least about 10%, at least about 20%, at least about
25%, at least about 50%, at least about 60%, at least about 70%, at
least about 80%, at least about 90%, or at least about 95%. In
other embodiments, inhibit means a decrease in metalloenzyme
activity of about 5% to about 25%, about 25% to about 50%, about
50% to about 75%, or about 75% to 100%. In some embodiments,
inhibit means a decrease in metalloenzyme activity of about 95% to
100%, e.g., a decrease in activity of 95%, 96%, 97%, 98%, 99%, or
100%. Such decreases can be measured using a variety of techniques
that would be recognizable by one of skill in the art. Particular
assays for measuring individual activity are described below.
[0059] Furthermore the compounds of the invention include olefins
having either geometry: "Z" refers to what is referred to as a
"cis" (same side) configuration whereas "E" refers to what is
referred to as a "trans" (opposite side) configuration. With
respect to the nomenclature of a chiral center, the terms "d" and
"1" configuration are as defined by the IUPAC Recommendations. As
to the use of the terms, diastereomer, racemate, epimer and
enantiomer, these will be used in their normal context to describe
the stereochemistry of preparations.
[0060] As used throughout this specification, the term `R` refers
to the group consisting of C.sub.1-8 alkyl, C.sub.2-8 alkenyl or
C.sub.2-8 alkynyl, unless stated otherwise.
[0061] As used herein, the term "alkyl" refers to a
straight-chained or branched hydrocarbon group containing 1 to 12
carbon atoms. The term "lower alkyl" refers to a C.sub.1-C.sub.6
alkyl chain. Examples of alkyl groups include methyl, ethyl,
n-propyl, isopropyl, tert-butyl, and n-pentyl. Alkyl groups may be
optionally substituted with one or more substituents.
[0062] The term "haloalkyl" refers to an alkyl group that is
substituted by one or more halo substituents. Examples of haloalkyl
groups include fluoromethyl, difluoromethyl, trifluoromethyl,
bromomethyl, chloromethyl, and 2,2,2-trifluoroethyl.
[0063] The term "alkenyl" refers to an unsaturated hydrocarbon
chain that may be a straight chain or branched chain, containing 2
to 12 carbon atoms and at least one carbon-carbon double bond.
Alkenyl groups may be optionally substituted with one or more
substituents.
[0064] The term "alkynyl" refers to an unsaturated hydrocarbon
chain that may be a straight chain or branched chain, containing
the 2 to 12 carbon atoms and at least one carbon-carbon triple
bond. Alkynyl groups may be optionally substituted with one or more
substituents.
[0065] The sp.sup.2 or sp carbons of an alkenyl group and an
alkynyl group, respectively, may optionally be the point of
attachment of the alkenyl or alkynyl groups.
[0066] The term "alkoxy" refers to an --OR substituent.
[0067] The term "(haloalkoxy)alkyl" refers to an alkyl substituent
which is further substituted with 1, 2 or 3 haloalkoxy groups.
[0068] The term "halocycloalkoxy" refers to an --OR substituent
where R is a cycloalkyl group that is further substituted with 1 or
more halogens.
[0069] As used herein, the term "halogen", "hal" or "halo" means
--F, --Cl, --Br or --I. The term "haloalkoxy" refers to an --OR
substituent where R is fully or partially substituted with Cl, F, I
or Br or any combination thereof. Examples of haloalkoxy groups
include trifluoromethoxy, and 2,2,2-trifluoroethoxy.
[0070] The term "cycloalkyl" refers to a hydrocarbon 3-8 membered
monocyclic or 7-14 membered bicyclic ring system having at least
one saturated ring or having at least one non-aromatic ring,
wherein the non-aromatic ring may have some degree of unsaturation.
Cycloalkyl groups may be optionally substituted with one or more
substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each
ring of a cycloalkyl group may be substituted by a substituent.
Representative examples of cycloalkyl group include cyclopropyl,
cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl,
cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
[0071] The term "aryl" refers to a hydrocarbon monocyclic, bicyclic
or tricyclic aromatic ring system. Aryl groups may be optionally
substituted with one or more substituents. In one embodiment, 0, 1,
2, 3, 4, 5 or 6 atoms of each ring of an aryl group may be
substituted by a substituent. Examples of aryl groups include
phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and
the like.
[0072] The term "heteroaryl" refers to an aromatic 5-8 membered
monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic
ring system having 1-4 ring heteroatoms if monocyclic, 1-6
heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said
heteroatoms selected from O, N, or S, and the remaining ring atoms
being carbon (with appropriate hydrogen atoms unless otherwise
indicated). Heteroaryl groups may be optionally substituted with
one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms
of each ring of a heteroaryl group may be substituted by a
substituent. Examples of heteroaryl groups include pyridyl,
furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl,
thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl,
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl,
indazolyl, and the like.
[0073] The term "nitrogen-containing heteroaryl" refers to a
heteroaryl group having 1-4 ring nitrogen heteroatoms if
monocyclic, 1-6 ring nitrogen heteroatoms if bicyclic, or 1-9 ring
nitrogen heteroatoms if tricyclic.
[0074] The term "heterocycloalkyl" refers to a nonaromatic 3-8
membered monocyclic, 7-12 membered bicyclic, or 10-14 membered
tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6
heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said
heteroatoms selected from O, N, S, B, P or Si, wherein the
nonaromatic ring system is completely saturated. Heterocycloalkyl
groups may be optionally substituted with one or more substituents.
In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a
heterocycloalkyl group may be substituted by a substituent.
Representative heterocycloalkyl groups include piperidinyl,
piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl,
1,3-dioxolane, tetrahydrofuranyl, tetrahydrothienyl, thiirenyl, and
the like.
[0075] The term "alkylamino" refers to an amino substituent which
is further substituted with one or two alkyl groups. The term
"aminoalkyl" refers to an alkyl substituent which is further
substituted with one or more amino groups. The term "hydroxyalkyl"
or "hydroxylalkyl" refers to an alkyl substituent which is further
substituted with one or more hydroxyl groups. The alkyl or aryl
portion of alkylamino, aminoalkyl, mercaptoalkyl, hydroxyalkyl,
mercaptoalkoxy, sulfonylalkyl, sulfonylaryl, alkylcarbonyl, and
alkylcarbonylalkyl may be optionally substituted with one or more
substituents.
[0076] The term "(heteroaryl)alkyl" refers to an alkyl substituent
which is further substituted with 1, 2 or 3 heteroaryl groups.
[0077] Acids and bases useful in the methods herein are known in
the art. Acid catalysts are any acidic chemical, which can be
inorganic (e.g., hydrochloric, sulfuric, nitric acids, aluminum
trichloride) or organic (e.g., camphorsulfonic acid,
p-toluenesulfonic acid, acetic acid, ytterbium triflate) in nature.
Acids are useful in either catalytic or stoichiometric amounts to
facilitate chemical reactions. Bases are any basic chemical, which
can be inorganic (e.g., sodium bicarbonate, potassium hydroxide) or
organic (e.g., triethylamine, pyridine) in nature. Bases are useful
in either catalytic or stoichiometric amounts to facilitate
chemical reactions.
[0078] Alkylating agents are any reagent that is capable of
effecting the alkylation of the functional group at issue (e.g.,
oxygen atom of an alcohol, nitrogen atom of an amino group).
Alkylating agents are known in the art, including in the references
cited herein, and include alkyl halides (e.g., methyl iodide,
benzyl bromide or chloride), alkyl sulfates (e.g., methyl sulfate),
or other alkyl group-leaving group combinations known in the art.
Leaving groups are any stable species that can detach from a
molecule during a reaction (e.g., elimination reaction,
substitution reaction) and are known in the art, including in the
references cited herein, and include halides (e.g., I--, Cl--,
Br--, F--), hydroxy, alkoxy (e.g., --OMe, --O-t-Bu), acyloxy anions
(e.g., --OAc, --OC(O)CF.sub.3), sulfonates (e.g., mesyl, tosyl),
acetamides (e.g., --NHC(O)Me), carbamates (e.g., N(Me)C(O)Ot-Bu),
phosphonates (e.g., --OP(O)(OEt).sub.2), water or alcohols (protic
conditions), and the like.
[0079] In certain embodiments, substituents on any group (such as,
for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl,
heteroaralkyl, cycloalkyl, heterocycloalkyl) can be at any atom of
that group, wherein any group that can be substituted (such as, for
example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl,
heteroaralkyl, cycloalkyl, heterocycloalkyl) can be optionally
substituted with one or more substituents (which may be the same or
different), each replacing a hydrogen atom. Examples of suitable
substituents include, but are not limited to alkyl, alkenyl,
alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl,
aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy,
aryloxy, hydroxyl, hydroxylalkyl, oxo (i.e., carbonyl), carboxyl,
formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,
alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy,
heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl,
amino, aminoalkyl, dialkylamino, alkylcarbonylamino,
alkylaminocarbonyl, alkoxycarbonylamino, alkylamino, arylamino,
diarylamino, alkylcarbonyl, or arylamino-substituted aryl;
arylalkylamino, aralkylaminocarbonyl, amido, alkylaminosulfonyl,
arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino,
arylsulfonylamino, imino, carbamido, carbamyl, thioureido,
thiocyanato, sulfoamido, sulfonylalkyl, sulfonylaryl,
mercaptoalkoxy, N-hydroxyamidinyl, or N'-aryl,
N''-hydroxyamidinyl.
[0080] Compounds of the invention can be made by means known in the
art of organic synthesis. Methods for optimizing reaction
conditions, if necessary minimizing competing by-products, are
known in the art. Reaction optimization and scale-up may
advantageously utilize high-speed parallel synthesis equipment and
computer-controlled microreactors (e.g. Design And Optimization in
Organic Synthesis, 2.sup.nd Edition, Carlson R, Ed, 2005; Elsevier
Science Ltd; Jahnisch, K et al., Angew. Chem. Int. Ed. Engl. 2004,
43, 406; and references therein). Additional reaction schemes and
protocols may be determined by the skilled artisan by use of
commercially available structure-searchable database software, for
instance, SciFinder.RTM. (Chemical Abstracts Service (CAS.RTM.)
division of the American Chemical Society) and CrossFire
Beilstein.RTM. (Elsevier MDL), or by appropriate keyword searching
using an internet search engine such as Google.RTM. or keyword
databases such as the US Patent and Trademark Office text
database.
[0081] The compounds herein may also contain linkages (e.g.,
carbon-carbon bonds) wherein bond rotation is restricted about that
particular linkage, e.g. restriction resulting from the presence of
a ring or double bond. Accordingly, all cis/trans and E/Z isomers
are expressly included in the present invention. The compounds
herein may also be represented in multiple tautomeric forms; in
such instances, the invention expressly includes all tautomeric
forms of the compounds described herein, even though only a single
tautomeric form may be represented. All such isomeric forms of such
compounds herein are expressly included in the present invention.
All crystal forms and polymorphs of the compounds described herein
are expressly included in the present invention. Also embodied are
extracts and fractions comprising compounds of the invention. The
term "isomers" is intended to include diastereoisomers,
enantiomers, regioisomers, structural isomers, rotational isomers,
tautomers, and the like. For compounds which contain one or more
stereogenic centers, e.g., chiral compounds, the methods of the
invention may be carried out with an enantiomerically enriched
compound, a racemate, or a mixture of diastereomers.
[0082] An example of tautomeric forms is shown below wherein when
R.sub.1 is H, Formula B is a tautomeric form of Formula A.
##STR00003##
[0083] Preferred enantiomerically enriched compounds have an
enantiomeric excess of 50% or more, more preferably the compound
has an enantiomeric excess of 60%, 70%, 80%, 90%, 95%, 98%, or 99%
or more. In preferred embodiments, only one enantiomer or
diastereomer of a chiral compound of the invention is administered
to cells or a subject.
Methods of Treatment
[0084] In one aspect, the invention provides a method of modulating
the metalloenzyme activity of a cell in a subject, comprising
contacting the subject with a compound as described herein (e.g.,
of any formulae herein), in an amount and under conditions
sufficient to modulate metalloenzyme activity.
[0085] In one embodiment, the modulation is inhibition.
[0086] In another aspect, the invention provides a method of
treating a subject suffering from or susceptible to a
metalloenzyme-mediated disorder or disease, comprising
administering to the subject an effective amount of a compound as
described herein (e.g., of any formulae herein) or pharmaceutical
or agricultural composition thereof.
[0087] In other aspects, the invention provides a method of
treating a subject suffering from or susceptible to a
metalloenzyme-mediated disorder or disease, wherein the subject has
been identified as in need of treatment for a
metalloenzyme-mediated disorder or disease, comprising
administering to said subject in need thereof, an effective amount
of a compound as described herein (e.g., of any formulae herein) or
pharmaceutical or agricultural composition thereof, such that said
subject is treated for said disorder.
[0088] In certain embodiments, the invention provides a method of
treating a disease, disorder or symptom thereof, wherein the
disorder is cancer, cardiovascular disease, inflammatory disease or
infectious disease. In other embodiments the disease, disorder or
symptom thereof is metabolic disease, ophthalmologic disease,
central nervous system (CNS) disease, urologic disease, or
gastrointestinal disease. In certain embodiments the disease is
prostate cancer, breast cancer, inflammatory bowel disease,
psoriasis, systemic fungal infection, skin structure fungal
infection, mucosal fungal infection, and onychomycosis.
[0089] In certain embodiments, the subject is a mammal, preferably
a primate or human.
[0090] In another embodiment, the invention provides a method as
described above, wherein the effective amount of the compound as
described herein (e.g., of any formulae herein) is as described
above.
[0091] In another embodiment, the invention provides a method as
described above, wherein the compound as described herein (e.g., of
any formulae herein) is administered intravenously,
intramuscularly, subcutaneously, intracerebroventricularly, orally
or topically.
[0092] In other embodiments, the invention provides a method as
described above, wherein the compound as described herein (e.g., of
any formulae herein) is administered alone or in combination with
one or more other therapeutics. In a further embodiment, the
additional therapeutic agent is an anti-cancer agent, antifungal
agent, cardiovascular agent, antiinflammatory agent,
chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic
agent, an anti-proliferation agent, metabolic disease agent,
ophthalmologic disease agent, central nervous system (CNS) disease
agent, urologic disease agent, or gastrointestinal disease
agent.
[0093] Another object of the present invention is the use of a
compound as described herein (e.g., of any formulae herein) in the
manufacture of a medicament for use in the treatment of a
metalloenzyme-mediated disorder or disease. Another object of the
present invention is the use of a compound as described herein
(e.g., of any formulae herein) for use in the treatment of a
metalloenzyme-mediated disorder or disease. Another object of the
present invention is the use of a compound as described herein
(e.g., of any formulae herein) in the manufacture of an
agricultural composition for use in the treatment or prevention of
a metalloenzyme-mediated disorder or disease in agricultural or
agrarian settings.
Pharmaceutical Compositions
[0094] In one aspect, the invention provides a pharmaceutical
composition comprising the compound as described herein (e.g., of
any formulae herein) and a pharmaceutically acceptable carrier.
[0095] In another embodiment, the invention provides a
pharmaceutical composition further comprising an additional
therapeutic agent. In a further embodiment, the additional
therapeutic agent is an anti-cancer agent, antifungal agent,
cardiovascular agent, antiinflammatory agent, chemotherapeutic
agent, an anti-angiogenesis agent, cytotoxic agent, an
anti-proliferation agent, metabolic disease agent, ophthalmologic
disease agent, central nervous system (CNS) disease agent, urologic
disease agent, or gastrointestinal disease agent.
[0096] In one aspect, the invention provides a kit comprising an
effective amount of a compound as described herein (e.g., of any
formulae herein), in unit dosage form, together with instructions
for administering the compound to a subject suffering from or
susceptible to a metalloenzyme-mediated disease or disorder,
including cancer, solid tumor, cardiovascular disease, inflammatory
disease, infectious disease. In other embodiments the disease,
disorder or symptom thereof is metabolic disease, ophthalmologic
disease, central nervous system (CNS) disease, urologic disease, or
gastrointestinal disease.
[0097] The term "pharmaceutically acceptable salts" or
"pharmaceutically acceptable carrier" is meant to include salts of
the active compounds which are prepared with relatively nontoxic
acids or bases, depending on the particular substituents found on
the compounds described herein. When compounds of the present
invention contain relatively acidic functionalities, base addition
salts can be obtained by contacting the neutral form of such
compounds with a sufficient amount of the desired base, either neat
or in a suitable inert solvent. Examples of pharmaceutically
acceptable base addition salts include sodium, potassium, calcium,
ammonium, organic amino, or magnesium salt, or a similar salt. When
compounds of the present invention contain relatively basic
functionalities, acid addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired acid, either neat or in a suitable inert solvent. Examples
of pharmaceutically acceptable acid addition salts include those
derived from inorganic acids like hydrochloric, hydrobromic,
nitric, carbonic, monohydrogencarbonic, phosphoric,
monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,
monohydrogensulfuric, hydroiodic, or phosphorous acids and the
like, as well as the salts derived from relatively nontoxic organic
acids like acetic, propionic, isobutyric, maleic, malonic, benzoic,
succinic, suberic, fumaric, lactic, mandelic, phthalic,
benzenesulfonic, p-tolylsulfonic, citric, tartaric,
methanesulfonic, and the like. Also included are salts of amino
acids such as arginate and the like, and salts of organic acids
like glucuronic or galactunoric acids and the like (see, e.g.,
Berge et al., J. Pharm. Sci. 1977, 66, 1-19). Certain specific
compounds of the present invention contain both basic and acidic
functionalities that allow the compounds to be converted into
either base or acid addition salts. Other pharmaceutically
acceptable carriers known to those of skill in the art are suitable
for the present invention.
[0098] The neutral forms of the compounds may be regenerated by
contacting the salt with a base or acid and isolating the parent
compound in the conventional manner. The parent form of the
compound differs from the various salt forms in certain physical
properties, such as solubility in polar solvents, but otherwise the
salts are equivalent to the parent form of the compound for the
purposes of the present invention.
[0099] In addition to salt forms, the present invention provides
compounds which are in a prodrug form. Prodrugs of the compounds
described herein are those compounds that readily undergo chemical
changes under physiological conditions to provide the compounds of
the present invention. Additionally, prodrugs can be converted to
the compounds of the present invention by chemical or biochemical
methods in an ex vivo environment. For example, prodrugs can be
slowly converted to the compounds of the present invention when
placed in a transdermal patch reservoir with a suitable enzyme or
chemical reagent.
[0100] Certain compounds of the present invention can exist in
unsolvated forms as well as solvated forms, including hydrated
forms. In general, the solvated forms are equivalent to unsolvated
forms and are intended to be encompassed within the scope of the
present invention. Certain compounds of the present invention may
exist in multiple crystalline or amorphous forms. In general, all
physical forms are equivalent for the uses contemplated by the
present invention and are intended to be within the scope of the
present invention.
[0101] The invention also provides a pharmaceutical composition,
comprising an effective amount a compound described herein and a
pharmaceutically acceptable carrier. In an embodiment, compound is
administered to the subject using a pharmaceutically-acceptable
formulation, e.g., a pharmaceutically-acceptable formulation that
provides sustained delivery of the compound to a subject for at
least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks,
three weeks, or four weeks after the pharmaceutically-acceptable
formulation is administered to the subject.
[0102] Actual dosage levels and time course of administration of
the active ingredients in the pharmaceutical compositions of this
invention may be varied so as to obtain an amount of the active
ingredient which is effective to achieve the desired therapeutic
response for a particular patient, composition, and mode of
administration, without being toxic (or unacceptably toxic) to the
patient.
[0103] In use, at least one compound according to the present
invention is administered in a pharmaceutically effective amount to
a subject in need thereof in a pharmaceutical carrier by
intravenous, intramuscular, subcutaneous, or
intracerebroventricular injection or by oral administration or
topical application. In accordance with the present invention, a
compound of the invention may be administered alone or in
conjunction with a second, different therapeutic. By "in
conjunction with" is meant together, substantially simultaneously
or sequentially. In one embodiment, a compound of the invention is
administered acutely. The compound of the invention may therefore
be administered for a short course of treatment, such as for about
1 day to about 1 week. In another embodiment, the compound of the
invention may be administered over a longer period of time to
ameliorate chronic disorders, such as, for example, for about one
week to several months depending upon the condition to be
treated.
[0104] By "pharmaceutically effective amount" as used herein is
meant an amount of a compound of the invention, high enough to
significantly positively modify the condition to be treated but low
enough to avoid serious side effects (at a reasonable benefit/risk
ratio), within the scope of sound medical judgment. A
pharmaceutically effective amount of a compound of the invention
will vary with the particular goal to be achieved, the age and
physical condition of the patient being treated, the severity of
the underlying disease, the duration of treatment, the nature of
concurrent therapy and the specific compound employed. For example,
a therapeutically effective amount of a compound of the invention
administered to a child or a neonate will be reduced
proportionately in accordance with sound medical judgment. The
effective amount of a compound of the invention will thus be the
minimum amount which will provide the desired effect.
[0105] A decided practical advantage of the present invention is
that the compound may be administered in a convenient manner such
as by intravenous, intramuscular, subcutaneous, oral or
intracerebroventricular injection routes or by topical application,
such as in creams or gels. Depending on the route of
administration, the active ingredients which comprise a compound of
the invention may be required to be coated in a material to protect
the compound from the action of enzymes, acids and other natural
conditions which may inactivate the compound. In order to
administer a compound of the invention by other than parenteral
administration, the compound can be coated by, or administered
with, a material to prevent inactivation.
[0106] The compound may be administered parenterally or
intraperitoneally. Dispersions can also be prepared, for example,
in glycerol, liquid polyethylene glycols, and mixtures thereof, and
in oils.
[0107] Some examples of substances which can serve as
pharmaceutical carriers are sugars, such as lactose, glucose and
sucrose; starches such as corn starch and potato starch; cellulose
and its derivatives such as sodium carboxymethylcellulose,
ethylcellulose and cellulose acetates; powdered tragancanth; malt;
gelatin; talc; stearic acids; magnesium stearate; calcium sulfate;
vegetable oils, such as peanut oils, cottonseed oil, sesame oil,
olive oil, corn oil and oil of theobroma; polyols such as propylene
glycol, glycerine, sorbitol, mannitol, and polyethylene glycol;
agar; alginic acids; pyrogen-free water; isotonic saline; and
phosphate buffer solution; skim milk powder; as well as other
non-toxic compatible substances used in pharmaceutical formulations
such as Vitamin C, estrogen and Echinacea, for example. Wetting
agents and lubricants such as sodium lauryl sulfate, as well as
coloring agents, flavoring agents, lubricants, excipients,
tableting agents, stabilizers, anti-oxidants and preservatives, can
also be present. Solubilizing agents, including for example,
cremaphore and beta-cyclodextrins can also used in the
pharmaceutical compositions herein.
[0108] Pharmaceutical compositions comprising the active compounds
of the presently disclosed subject matter (or prodrugs thereof) can
be manufactured by means of conventional mixing, dissolving,
granulating, dragee-making levigating, emulsifying, encapsulating,
entrapping or lyophilization processes. The compositions can be
formulated in conventional manner using one or more physiologically
acceptable carriers, diluents, excipients or auxiliaries which
facilitate processing of the active compounds into preparations
which can be used pharmaceutically.
[0109] Pharmaceutical compositions of the presently disclosed
subject matter can take a form suitable for virtually any mode of
administration, including, for example, topical, ocular, oral,
buccal, systemic, nasal, injection, transdermal, rectal, vaginal,
and the like, or a form suitable for administration by inhalation
or insufflation.
[0110] For topical administration, the active compound(s) or
prodrug(s) can be formulated as solutions, gels, ointments, creams,
suspensions, and the like.
[0111] Systemic formulations include those designed for
administration by injection, e.g., subcutaneous, intravenous,
intramuscular, intrathecal or intraperitoneal injection, as well as
those designed for transdermal, transmucosal, oral, or pulmonary
administration.
[0112] Useful injectable preparations include sterile suspensions,
solutions or emulsions of the active compound(s) in aqueous or oily
vehicles. The compositions also can contain formulating agents,
such as suspending, stabilizing and/or dispersing agent. The
formulations for injection can be presented in unit dosage form
(e.g., in ampules or in multidose containers) and can contain added
preservatives.
[0113] Alternatively, the injectable formulation can be provided in
powder form for reconstitution with a suitable vehicle, including
but not limited to sterile pyrogen free water, buffer, dextrose
solution, and the like, before use. To this end, the active
compound(s) can be dried by any art-known technique, such as
lyophilization, and reconstituted prior to use.
[0114] For transmucosal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are known in the art.
[0115] For oral administration, the pharmaceutical compositions can
take the form of, for example, lozenges, tablets or capsules
prepared by conventional means with pharmaceutically acceptable
excipients such as binding agents (e.g., pregelatinized maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);
fillers (e.g., lactose, microcrystalline cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or
silica); disintegrants (e.g., potato starch or sodium starch
glycolate); or wetting agents (e.g., sodium lauryl sulfate). The
tablets can be coated by methods well known in the art with, for
example, sugars or enteric coatings.
[0116] Liquid preparations for oral administration can take the
form of, for example, elixirs, solutions, syrups or suspensions, or
they can be presented as a dry product for constitution with water
or other suitable vehicle before use. Such liquid preparations can
be prepared by conventional means with pharmaceutically acceptable
additives such as suspending agents (e.g., sorbitol syrup,
cellulose derivatives or hydrogenated edible fats); emulsifying
agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g.,
almond oil, oily esters, ethyl alcohol or fractionated vegetable
oils); and preservatives (e.g., methyl or propyl p-hydroxybenzoates
or sorbic acid). The preparations also can contain buffer salts,
preservatives, flavoring, coloring and sweetening agents as
appropriate.
[0117] Preparations for oral administration can be suitably
formulated to give controlled release of the active compound or
prodrug, as is well known.
[0118] For buccal administration, the compositions can take the
form of tablets or lozenges formulated in a conventional
manner.
[0119] For rectal and vaginal routes of administration, the active
compound(s) can be formulated as solutions (for retention enemas),
suppositories, or ointments containing conventional suppository
bases, such as cocoa butter or other glycerides.
[0120] For nasal administration or administration by inhalation or
insufflation, the active compound(s) or prodrug(s) can be
conveniently delivered in the form of an aerosol spray from
pressurized packs or a nebulizer with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, fluorocarbons, carbon dioxide or other
suitable gas. In the case of a pressurized aerosol, the dosage unit
can be determined by providing a valve to deliver a metered amount.
Capsules and cartridges for use in an inhaler or insufflator (for
example capsules and cartridges comprised of gelatin) can be
formulated containing a powder mix of the compound and a suitable
powder base such as lactose or starch.
[0121] A specific example of an aqueous suspension formulation
suitable for nasal administration using commercially-available
nasal spray devices includes the following ingredients: active
compound or prodrug (0.5-20 mg/mL); benzalkonium chloride (0.1-0.2
mg/mL); polysorbate 80 (TWEEN.RTM. 80; 0.5-5 mg/mL);
carboxymethylcellulose sodium or microcrystalline cellulose (1-15
mg/mL); phenylethanol (1-4 mg/mL); and dextrose (20-50 mg/mL). The
pH of the final suspension can be adjusted to range from about pH 5
to pH 7, with a pH of about pH 5.5 being typical.
[0122] For ocular administration, the active compound(s) or
prodrug(s) can be formulated as a solution, emulsion, suspension,
and the like, suitable for administration to the eye. A variety of
vehicles suitable for administering compounds to the eye are known
in the art. Specific non-limiting examples are described in U.S.
Pat. No. 6,261,547; U.S. Pat. No. 6,197,934; U.S. Pat. No.
6,056,950; U.S. Pat. No. 5,800,807; U.S. Pat. No. 5,776,445; U.S.
Pat. No. 5,698,219; U.S. Pat. No. 5,521,222; U.S. Pat. No.
5,403,841; U.S. Pat. No. 5,077,033; U.S. Pat. No. 4,882,150; and
U.S. Pat. No. 4,738,851, each of which is incorporated herein by
reference in its entirety.
[0123] For prolonged delivery, the active compound(s) or prodrug(s)
can be formulated as a depot preparation for administration by
implantation or intramuscular injection. The active ingredient can
be formulated with suitable polymeric or hydrophobic materials
(e.g., as an emulsion in an acceptable oil) or ion exchange resins,
or as sparingly soluble derivatives, e.g., as a sparingly soluble
salt. Alternatively, transdermal delivery systems manufactured as
an adhesive disc or patch which slowly releases the active
compound(s) for percutaneous absorption can be used. To this end,
permeation enhancers can be used to facilitate transdermal
penetration of the active compound(s). Suitable transdermal patches
are described in for example, U.S. Pat. No. 5,407,713; U.S. Pat.
No. 5,352,456; U.S. Pat. No. 5,332,213; U.S. Pat. No. 5,336,168;
U.S. Pat. No. 5,290,561; U.S. Pat. No. 5,254,346; U.S. Pat. No.
5,164,189; U.S. Pat. No. 5,163,899; U.S. Pat. No. 5,088,977; U.S.
Pat. No. 5,087,240; U.S. Pat. No. 5,008,110; and U.S. Pat. No.
4,921,475, each of which is incorporated herein by reference in its
entirety.
[0124] Alternatively, other pharmaceutical delivery systems can be
employed. Liposomes and emulsions are well-known examples of
delivery vehicles that can be used to deliver active compound(s) or
prodrug(s). Certain organic solvents such as dimethylsulfoxide
(DMSO) also can be employed.
[0125] The pharmaceutical compositions can, if desired, be
presented in a pack or dispenser device which can contain one or
more unit dosage forms containing the active compound(s). The pack
can, for example, comprise metal or plastic foil, such as a blister
pack. The pack or dispenser device can be accompanied by
instructions for administration.
[0126] The active compound(s) or prodrug(s) of the presently
disclosed subject matter, or compositions thereof, will generally
be used in an amount effective to achieve the intended result, for
example in an amount effective to treat or prevent the particular
disease being treated. The compound(s) can be administered
therapeutically to achieve therapeutic benefit or prophylactically
to achieve prophylactic benefit. By therapeutic benefit is meant
eradication or amelioration of the underlying disorder being
treated and/or eradication or amelioration of one or more of the
symptoms associated with the underlying disorder such that the
patient reports an improvement in feeling or condition,
notwithstanding that the patient can still be afflicted with the
underlying disorder. For example, administration of a compound to a
patient suffering from an allergy provides therapeutic benefit not
only when the underlying allergic response is eradicated or
ameliorated, but also when the patient reports a decrease in the
severity or duration of the symptoms associated with the allergy
following exposure to the allergen. As another example, therapeutic
benefit in the context of asthma includes an improvement in
respiration following the onset of an asthmatic attack, or a
reduction in the frequency or severity of asthmatic episodes.
Therapeutic benefit also includes halting or slowing the
progression of the disease, regardless of whether improvement is
realized.
[0127] For prophylactic administration, the compound can be
administered to a patient at risk of developing one of the
previously described diseases. A patient at risk of developing a
disease can be a patient having characteristics placing the patient
in a designated group of at risk patients, as defined by an
appropriate medical professional or group. A patient at risk may
also be a patient that is commonly or routinely in a setting where
development of the underlying disease that may be treated by
administration of a metalloenzyme inhibitor according to the
invention could occur. In other words, the at risk patient is one
who is commonly or routinely exposed to the disease or illness
causing conditions or may be acutely exposed for a limited time.
Alternatively, prophylactic administration can be applied to avoid
the onset of symptoms in a patient diagnosed with the underlying
disorder.
[0128] The amount of compound administered will depend upon a
variety of factors, including, for example, the particular
indication being treated, the mode of administration, whether the
desired benefit is prophylactic or therapeutic, the severity of the
indication being treated and the age and weight of the patient, the
bioavailability of the particular active compound, and the like.
Determination of an effective dosage is well within the
capabilities of those skilled in the art.
[0129] Effective dosages can be estimated initially from in vitro
assays. For example, an initial dosage for use in animals can be
formulated to achieve a circulating blood or serum concentration of
active compound that is at or above an IC.sub.50 of the particular
compound as measured in as in vitro assay, such as the in vitro
fungal MIC or MFC and other in vitro assays described in the
Examples section. Calculating dosages to achieve such circulating
blood or serum concentrations taking into account the
bioavailability of the particular compound is well within the
capabilities of skilled artisans. For guidance, see Fingl &
Woodbury, "General Principles," In: Goodman and Gilman's The
Pharmaceutical Basis of Therapeutics, Chapter 1, pp. 1-46, 12th
edition, McGraw-Hill Professional, and the references cited
therein, which are incorporated herein by reference.
[0130] Initial dosages also can be estimated from in vivo data,
such as animal models. Animal models useful for testing the
efficacy of compounds to treat or prevent the various diseases
described above are well-known in the art.
[0131] Dosage amounts will typically be in the range of from about
0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, but can
be higher or lower, depending upon, among other factors, the
activity of the compound, its bioavailability, the mode of
administration, and various factors discussed above. Dosage amount
and interval can be adjusted individually to provide plasma levels
of the compound(s) which are sufficient to maintain therapeutic or
prophylactic effect. In cases of local administration or selective
uptake, such as local topical administration, the effective local
concentration of active compound(s) cannot be related to plasma
concentration. Skilled artisans will be able to optimize effective
local dosages without undue experimentation.
[0132] The compound(s) can be administered once per day, a few or
several times per day, or even multiple times per day, depending
upon, among other things, the indication being treated and the
judgment of the prescribing physician.
[0133] Preferably, the compound(s) will provide therapeutic or
prophylactic benefit without causing substantial toxicity. Toxicity
of the compound(s) can be determined using standard pharmaceutical
procedures. The dose ratio between toxic and therapeutic (or
prophylactic) effect is the therapeutic index. Compounds(s) that
exhibit high therapeutic indices are preferred.
[0134] The recitation of a listing of chemical groups in any
definition of a variable herein includes definitions of that
variable as any single group or combination of listed groups. The
recitation of an embodiment for a variable herein includes that
embodiment as any single embodiment or in combination with any
other embodiments or portions thereof. The recitation of an
embodiment herein includes that embodiment as any single embodiment
or in combination with any other embodiments or portions
thereof.
Agricultural Applications
[0135] Compounds of Formula I may be formulated into agriculturally
acceptable acid addition salts. By way of a non-limiting example,
an amine function can form salts with hydrochloric, hydrobromic,
sulfuric, phosphoric, acetic, benzoic, citric, malonic, salicylic,
malic, fumaric, oxalic, succinic, tartaric, lactic, gluconic,
ascorbic, maleic, aspartic, benzenesulfonic, methanesulfonic,
ethanesulfonic, hydroxymethanesulfonic, and hydroxyethanesulfonic
acids. Additionally, by way of a non-limiting example, an acid
function can form salts including those derived from alkali or
alkaline earth metals and those derived from ammonia and amines.
Examples of preferred cations include sodium, potassium, and
magnesium.
[0136] Compounds of Formula I may be formulated into salt
derivatives. By way of a non-limiting example, a salt derivative
can be prepared by contacting a free base with a sufficient amount
of the desired acid to produce a salt. A free base may be
regenerated by treating the salt with a suitable dilute aqueous
base solution such as dilute aqueous sodium hydroxide (NaOH),
potassium carbonate, ammonia, and sodium bicarbonate. As an
example, in many cases, a pesticide, such as 2,4-D, is made more
water-soluble by converting it to its dimethylamine salt.
Suitable salts include those derived from alkali or alkaline earth
metals and those derived from ammonia and amines. Preferred cations
include sodium, potassium, magnesium, and aminium cations of the
formula:
R.sup.9R.sup.10R.sup.11R.sup.12N.sup.+
wherein R.sup.9, R.sup.10, R.sup.11 and R.sup.12 each,
independently represents hydrogen or C.sub.1-C.sub.12 alkyl,
C.sub.3-C.sub.12 alkenyl or C.sub.3-C.sub.12 alkynyl, each of which
is optionally substituted by one or more hydroxy, C.sub.1-C.sub.4
alkoxy, C.sub.1-C.sub.4 alkylthio or phenyl groups, provided that
R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are sterically compatible.
Additionally, any two of R.sup.9, R.sup.10, R.sup.11 and R.sup.12
together may represent an aliphatic difunctional moiety containing
one to twelve carbon atoms and up to two oxygen or sulfur atoms.
Salts of the compounds of Formula I can be prepared by treatment of
compounds of Formula I with a metal hydroxide, such as sodium
hydroxide, with an amine, such as ammonia, trimethylamine,
diethanolamine, 2-methylthiopropylamine, bisallylamine,
2-butoxyethylamine, morpholine, cyclododecylamine, or benzylamine
or with a tetraalkylammonium hydroxide, such as tetramethylammonium
hydroxide or choline hydroxide Amine salts are often preferred
forms of the compounds of Formula I because they are water-soluble
and lend themselves to the preparation of desirable aqueous based
herbicidal compositions.
[0137] The compounds and compositions herein can be used in methods
of modulating metalloenzyme activity in a microorganism on a plant
comprising contacting a compound herein with the plant (e.g., seed,
seedling, grass, weed, grain). The compounds and compositions
herein can be used to treat a plant, field or other agricultural
area (e.g., as herbicides, pesticides, growth regulators, etc.) by
administering the compound or composition (e.g., contacting,
applying, spraying, atomizing, dusting, etc.) to the subject plant,
field or other agricultural area. The administration can be either
pre- or post-emergence. The administration can be either as a
treatment or preventative regimen.
[0138] One aspect is a method of treating or preventing a fungal
disease or disorder in or on a plant comprising contacting a
compound (or composition) of any of the formulae herein with the
plant. Another aspect is a method of treating or preventing fungi
growth in or on a plant comprising contacting a compound (or
composition) of any of the formulae herein with the plant. Another
aspect is a method of inhibiting microorganisms in or on a plant
comprising contacting a compound (or composition) of any of the
formulae herein with the plant.
[0139] The compounds and compositions herein may be used in methods
of preventing or controlling pathogen induced diseases on a plant
comprising contacting a compound herein with the plant (e.g., seed,
seedling, grass, weed, grain) or an area adjacent to the plant. The
compounds and compositions herein may be used to treat a plant,
field or other agricultural area by administering the compound or
composition (e.g., contacting, applying, spraying, atomizing,
dusting, etc.) to the subject plant, field or other agricultural
area. The administration may be either pre- or post-emergence. The
administration may be either as a treatment or preventative
regimen. As such, the compounds, compositions and agricultural uses
herein include lawn, turf, ornamental vegetation, home and garden,
farming, range and pasture applications. The pathogen may be any on
a plant and include those delineated herein.
[0140] One embodiment of the present disclosure is a use of a
compound of Formula I, for protection of a plant against attack by
a phytopathogenic organism or the treatment of a plant infested by
a phytopathogenic organism, comprising the application of a
compound of Formula I, or a composition comprising the compound to
soil, a plant, a part of a plant, foliage, and/or seeds.
[0141] Additionally, another embodiment of the present disclosure
is a composition useful for protecting a plant against attack by a
phytopathogenic organism and/or treatment of a plant infested by a
phytopathogenic organism comprising a compound of Formula I and a
phytologically acceptable carrier material.
[0142] The compounds of the present disclosure may be applied by
any of a variety of known techniques, either as the compounds or as
formulations comprising the compounds. For example, the compounds
may be applied to the roots, seeds or foliage of plants for the
control of various fungi, without damaging the commercial value of
the plants.
[0143] The compounds herein can be used alone or in combination
with other agriculturally active agents. The use of the compounds
or compositions (and the compositions) herein can further comprise
an additional active agent such as an azole fungicide selected from
epoxiconazole, tebuconazole, fluquinconazole, flutriafol,
metconazole, myclobutanil, cycproconazole, prothioconazole and
propiconazole.
[0144] The use of the compounds or compositions (and the
compositions) herein can further comprise an additional active
agent such as an azole fungicide selected from the group
trifloxystrobin, pyraclostrobin, orysastrobin, fluoxastrobin and
azoxystrobin.
[0145] Preferably, the compounds of the present disclosure are
applied in the form of a formulation, comprising one or more of the
compounds of Formula I with an agriculturally or phytologically
acceptable carrier. The compositions comprising compounds herein
can be employed, for example, in the form of directly sprayable
aqueous solutions, powders, suspensions, also highly-concentrated
aqueous, oily or other suspensions or dispersions, emulsions, oil
dispersions, pastes, dusts, materials for spreading or granules, by
means of spraying, atomizing, dusting, spreading or pouring.
[0146] The present disclosure contemplates all vehicles by which
one or more of the compounds may be formulated for delivery and use
as a fungicide. Typically, formulations are applied as aqueous
suspensions or emulsions. Aqueous use forms can be prepared from
emulsion concentrates, suspensions, pastes, wettable powders or
water-dispersible granules by adding water. To prepare emulsions,
pastes or oil dispersions, the substances, as such or dissolved in
an oil or solvent, can be homogenized in water by means of wetting
agent, tackifier, dispersant or emulsifier. However, it is also
possible to prepare concentrates composed of active substance,
wetting agent, tackifier, dispersant or emulsifier and, if
appropriate, solvent or oil, and these concentrates are suitable
for dilution with water.
[0147] Wettable powders, which may be compacted to form water
dispersible granules, comprise an intimate mixture of one or more
of the compounds of Formula I, an inert carrier and surfactants.
The concentration of the compound in the wettable powder may be
from about 10 percent to about 90 percent by weight based on the
total weight of the wettable powder, more preferably about 25
weight percent to about 75 weight percent. In the preparation of
wettable powder formulations, the compounds may be compounded with
any finely divided solid, such as prophyllite, talc, chalk, gypsum,
Fuller's earth, bentonite, attapulgite, starch, casein, gluten,
montmorillonite clays, diatomaceous earths, purified silicates or
the like. In such operations, the finely divided carrier and
surfactants are typically blended with the compound(s) and
milled.
[0148] Granules, e.g. coated granules, impregnated granules and
homogeneous granules, can be prepared by binding the active
ingredients (e.g., compounds herein) to solid carriers. Solid
carriers are mineral earths such as silicas, silica gels,
silicates, talc, kaolin, limestone, lime, chalk, bole, loess, clay,
dolomite, diatomaceous earth, calcium sulfate, magnesium sulfate,
magnesium oxide, ground synthetic material, fertilizers such as
ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas and
products of vegetable origin such as cereal meal, tree bark meal,
wood meal and nutshell meal, cellulose powders or other solid
carriers.
[0149] The compounds herein can be formulated as ordinary tablets,
capsules, solids, liquids, emulsions, slurries, oils, fine granules
or powders, which are suitable for administration to plants, fields
or other agricultural areas. In preferred embodiments, the
preparation includes between 1 and 95% (e.g., 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 25%, 75%, 80%, 90%, 95%) compound herein in a carrier or
diluent. The compositions delineated herein include the compounds
of the formulae delineated herein, as well as additional
agricultural agents if present, in amounts effective for
controlling (e.g., modulating, inhibiting) a metalloenzyme-mediated
agricultural disease or disorder.
[0150] In one approach, a compound herein is provided in an
encapsulated formulation (liquid or powder). Specific materials
suitable for use in capsule materials include, but are not limited
to, porous particulates or substrates such as silica, perlite,
talc, clay, pyrophyllite, diatomaceous earth, gelatin and gels,
polymers (e.g., polyurea, polyurethane, polyamide, polyester,
etc.), polymeric particles, or cellulose. These include, for
example, hollow fibers, hollow tubes or tubing which release a
compound specified herein through the walls, capillary tubing which
releases the compound out of an opening in the tubing, polymeric
blocks of different shapes, e.g., strips, blocks, tablets, discs,
which release the compound out of the polymer matrix, membrane
systems which hold the compound within an impermeable container and
release it through a measured permeable membrane, and combinations
of the foregoing. Examples of such dispensing compositions are
polymer laminates, polyvinyl chloride pellets, and
microcapillaries.
[0151] Encapsulation processes are typically classified as chemical
or mechanical. Examples of chemical processes for encapsulation
include, but are not limited to, complex coacervation,
polymer-polymer incompatibility, interfacial polymerization in
liquid media, in situ polymerization, in-liquid drying, thermal and
ionic gelation in liquid media, desolvation in liquid media,
starch-based chemistry processes, trapping in cyclodextrins, and
formation of liposomes. Examples of mechanical processes for
encapsulation include, but are not limited to, spray drying, spray
chilling, fluidized bed, electrostatic deposition, centrifugal
extrusion, spinning disk or rotational suspension separation,
annular-jet encapsulation, polymerization at liquid-gas or
solid-gas interface, solvent evaporation, pressure extrusion or
spraying into solvent extraction bath.
[0152] Microcapsules are also suitable for the long-term release of
active compound herein. Microcapsules are small particles that
contain a core material or active ingredient surrounded by a
coating or shell. The size of the microcapsule typically varies
from 1 to 1000 microns with capsules smaller than 1 micron
classified as nanocapsules and capsules larger than 1000 microns as
macrocapsules. Core payload usually varies from 0.1 to 98 weight
percent. Microcapsules can have a variety of structures (continuous
core/shell, multinuclear, or monolithic) and have irregular or
geometric shapes.
[0153] In another approach, the compound herein is provided in an
oil-based delivery system. Oil release substrates include vegetable
and/or mineral oils. In one embodiment, the substrate also contains
a surface active agent that renders the composition readily
dispersable in water; such agents include wetting agents,
emulsifying agents, dispersing agents, and the like.
[0154] Compounds of the invention can also be provided as
emulsions. Emulsion formulations can be found as water in oil (w/o)
or oil in water (o/w). Droplet size can vary from the nanometer
scale (colloidal dispersion) to several hundred microns. A variety
of surfactants and thickeners are usually incorporated in the
formulation to modify the size of the droplets, stabilize the
emulsion, and modify the release.
[0155] Emulsifiable concentrates of the compounds of Formula I may
comprise a convenient concentration, such as from about 10 weight
percent to about 50 weight percent of the compound, in a suitable
liquid, based on the total weight of the concentrate. The compounds
may be dissolved in an inert carrier, which is either a
water-miscible solvent or a mixture of water-immiscible organic
solvents, and emulsifiers. The concentrates may be diluted with
water and oil to form spray mixtures in the form of oil-in-water
emulsions. Useful organic solvents include aromatics, especially
the high-boiling naphthalenic and olefinic portions of petroleum
such as heavy aromatic naphtha. Other organic solvents may also be
used, for example, terpenic solvents, including rosin derivatives,
aliphatic ketones, such as cyclohexanone, and complex alcohols,
such as 2-ethoxyethanol.
[0156] Emulsifiers which may be advantageously employed herein may
be readily determined by those skilled in the art and include
various nonionic, anionic, cationic and amphoteric emulsifiers, or
a blend of two or more emulsifiers. Examples of nonionic
emulsifiers useful in preparing the emulsifiable concentrates
include the polyalkylene glycol ethers and condensation products of
alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or
fatty acids with ethylene oxide, propylene oxides such as the
ethoxylated alkyl phenols and carboxylic esters solubilized with
the polyol or polyoxyalkylene. Cationic emulsifiers include
quaternary ammonium compounds and fatty amine salts. Anionic
emulsifiers include the oil-soluble salts (e.g., calcium) of
alkylaryl sulfonic acids, oil-soluble salts or sulfated polyglycol
ethers and appropriate salts of phosphated polyglycol ether.
[0157] Representative organic liquids which may be employed in
preparing the emulsifiable concentrates of the compounds of the
present invention are the aromatic liquids such as xylene, propyl
benzene fractions; or mixed naphthalene fractions, mineral oils,
substituted aromatic organic liquids such as dioctyl phthalate;
kerosene; dialkyl amides of various fatty acids, particularly the
dimethyl amides of fatty glycols and glycol derivatives such as the
n-butyl ether, ethyl ether or methyl ether of diethylene glycol,
the methyl ether of triethylene glycol, petroleum fractions or
hydrocarbons such as mineral oil, aromatic solvents, paraffinic
oils, and the like; vegetable oils such as soybean oil, rapeseed
oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn
oil, cottonseed oil, linseed oil, palm oil, peanut oil, safflower
oil, sesame oil, tung oil and the like; esters of the above
vegetable oils; and the like. Mixtures of two or more organic
liquids may also be employed in the preparation of the emulsifiable
concentrate. Organic liquids include xylene, and propyl benzene
fractions, with xylene being most preferred in some cases.
Surface-active dispersing agents are typically employed in liquid
formulations and in an amount of from 0.1 to 20 percent by weight
based on the combined weight of the dispersing agent with one or
more of the compounds. The formulations can also contain other
compatible additives, for example, plant growth regulators and
other biologically active compounds used in agriculture.
[0158] Aqueous suspensions comprise suspensions of one or more
water-insoluble compounds of Formula I, dispersed in an aqueous
vehicle at a concentration in the range from about 5 to about 50
weight percent, based on the total weight of the aqueous
suspension. Suspensions are prepared by finely grinding one or more
of the compounds, and vigorously mixing the ground material into a
vehicle comprised of water and surfactants chosen from the same
types discussed above. Other components, such as inorganic salts
and synthetic or natural gums, may also be added to increase the
density and viscosity of the aqueous vehicle. It is often most
effective to grind and mix at the same time by preparing the
aqueous mixture and homogenizing it in an implement such as a sand
mill, ball mill, or piston-type homogenizer.
[0159] Aqueous emulsions comprise emulsions of one or more
water-insoluble pesticidally active ingredients emulsified in an
aqueous vehicle at a concentration typically in the range from
about 5 to about 50 weight percent, based on the total weight of
the aqueous emulsion. If the pesticidally active ingredient is a
solid it must be dissolved in a suitable water-immiscible solvent
prior to the preparation of the aqueous emulsion. Emulsions are
prepared by emulsifying the liquid pesticidally active ingredient
or water-immiscible solution thereof into an aqueous medium
typically with inclusion of surfactants that aid in the formation
and stabilization of the emulsion as described above. This is often
accomplished with the aid of vigorous mixing provided by high shear
mixers or homogenizers.
[0160] The compounds of Formula I can also be applied as granular
formulations, which are particularly useful for applications to the
soil. Granular formulations generally contain from about 0.5 to
about 10 weight percent, based on the total weight of the granular
formulation of the compound(s), dispersed in an inert carrier which
consists entirely or in large part of coarsely divided inert
material such as attapulgite, bentonite, diatomite, clay or a
similar inexpensive substance. Such formulations are usually
prepared by dissolving the compounds in a suitable solvent and
applying it to a granular carrier which has been preformed to the
appropriate particle size, in the range of from about 0.5 to about
3 mm. A suitable solvent is a solvent in which the compound is
substantially or completely soluble. Such formulations may also be
prepared by making a dough or paste of the carrier and the compound
and solvent, and crushing and drying to obtain the desired granular
particle.
[0161] Alternatively, compounds of the invention may also be
formulated in a solid tablet and comprise (and preferably consist
essentially of) an oil, a protein/carbohydrate material (preferably
vegetable based), a sweetener and an active ingredient useful in
the prevention or treatment of a metalloenzyme-mediated
agricultural disease or disorder. In one embodiment the invention
provides a solid tablet and comprises (and preferably consist
essentially of) an oil, a protein/carbohydrate material (preferably
vegetable based), a sweetener and an active ingredient (e.g.,
compound herein or combinations or derivatives thereof) useful in
the prevention or treatment a metalloenzyme-mediated agricultural
disease or disorder. Tablets typically contain about 4-40% (e.g.,
5%, 10%, 20%, 30%, 40%) by weight of an oil (e.g., plant oil, such
as corn, sunflower, peanut, olive, grape seed, tung, turnip,
soybean, cottonseed, walnut, palm, castor, earth almond, hazelnut,
avocado, sesame, croton tiglium, cacao, linseed, rapeseed, and
canola oils and their hydrogenated derivatives; petroleum derived
oils (e.g., parafins and petroleum jelly), and other water
immiscible hydrocarbons (e.g., parafins). The tablets further
contain from about 5-40% (e.g., 5%, 10%, 20%, 30%, 40%) by weight
of a vegetable-based protein/carbohydrate material. The material
contains both a carbohydrate portion (e.g., derived from cereal
grains, such as wheat, rye, barley, oat, corn, rice, millet,
sorghum, birdseed, buckwheat, alfalfa, mielga, corn meal, soybean
meal, grain flour, wheat middlings, wheat bran, corn gluten meal,
algae meal, dried yeast, beans, rice) and a protein portion.
[0162] Optionally, various excipients and binders can be used in
order to assist with delivery of the active ingredient or to
provide the appropriate structure to the tablet. Preferred
excipients and binders include anhydrous lactose, microcrystalline
cellulose, corn starch, magnesium estearate, calcium estearate,
zinc estearate, sodium carboxymethylcellulose, ethyl cellulose,
hydroxypropyl methyl cellulose, and mixtures thereof.
[0163] Dusts containing the compounds of Formula I may be prepared
by intimately mixing one or more of the compounds in powdered form
with a suitable dusty agricultural carrier, such as, for example,
kaolin clay, ground volcanic rock, and the like. Dusts can suitably
contain from about 1 to about 10 weight percent of the compounds,
based on the total weight of the dust.
[0164] The formulations may additionally contain adjuvant
surfactants to enhance deposition, wetting and penetration of the
compounds onto the target crop and organism. These adjuvant
surfactants may optionally be employed as a component of the
formulation or as a tank mix. The amount of adjuvant surfactant
will typically vary from 0.01 to 1.0 percent by volume, based on a
spray-volume of water, preferably 0.05 to 0.5 volume percent.
Suitable adjuvant surfactants include, but are not limited to
ethoxylated nonyl phenols, ethoxylated synthetic or natural
alcohols, salts of the esters or sulfosuccinic acids, ethoxylated
organosilicones, ethoxylated fatty amines, blends of surfactants
with mineral or vegetable oils, crop oil concentrate (mineral oil
(85%)+emulsifiers (15%)); nonylphenol ethoxylate;
benzylcocoalkyldimethyl quaternary ammonium salt; blend of
petroleum hydrocarbon, alkyl esters, organic acid, and anionic
surfactant; C.sub.9-C.sub.11 alkylpolyglycoside; phosphated alcohol
ethoxylate; natural primary alcohol (C.sub.12-C.sub.16) ethoxylate;
di-sec-butylphenol EO-PO block copolymer; polysiloxane-methyl cap;
nonylphenol ethoxylate+urea ammonium nitrate; emulsified methylated
seed oil; tridecyl alcohol (synthetic) ethoxylate (8EO); tallow
amine ethoxylate (15 EO); PEG(400) dioleate-99. The formulations
may also include oil-in-water emulsions such as those disclosed in
U.S. patent application Ser. No. 11/495,228, the disclosure of
which is expressly incorporated by reference herein.
[0165] The formulations may optionally include combinations that
contain other pesticidal compounds. Such additional pesticidal
compounds may be fungicides, insecticides, herbicides, nematocides,
miticides, arthropodicides, bactericides or combinations thereof
that are compatible with the compounds of the present invention in
the medium selected for application, and not antagonistic to the
activity of the present compounds. Accordingly, in such
embodiments, the other pesticidal compound is employed as a
supplemental toxicant for the same or for a different pesticidal
use. The compounds of Formula I and the pesticidal compound in the
combination can generally be present in a weight ratio of from
1:100 to 100:1.
[0166] The compounds of the present disclosure may also be combined
with other fungicides to form fungicidal mixtures and synergistic
mixtures thereof. The fungicidal compounds of the present
disclosure are often applied in conjunction with one or more other
fungicides to control a wider variety of undesirable diseases. When
used in conjunction with other fungicide(s), the presently claimed
compounds may be formulated with the other fungicide(s), tank mixed
with the other fungicide(s) or applied sequentially with the other
fungicide(s). Such other fungicides may include
2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol,
8-hydroxyquinoline sulfate, ametoctradin, amisulbrom, antimycin,
Ampelomyces quisqualis, azaconazole, azoxystrobin, Bacillus
subtilis, benalaxyl, benomyl, benthiavalicarb-isopropyl,
benzylaminobenzene-sulfonate (BABS) salt, bicarbonates, biphenyl,
bismerthiazol, bitertanol, bixafen, blasticidin-S, borax, Bordeaux
mixture, boscalid, bromuconazole, bupirimate, calcium polysulfide,
captafol, captan, carbendazim, carboxin, carpropamid, carvone,
chloroneb, chlorothalonil, chlozolinate, Coniothyrium minitans,
copper hydroxide, copper octanoate, copper oxychloride, copper
sulfate, copper sulfate (tribasic), cuprous oxide, cyazofamid,
cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dazomet,
debacarb, diammonium ethylenebis-(dithiocarbamate), dichlofluanid,
dichlorophen, diclocymet, diclomezine, dichloran, diethofencarb,
difenoconazole, difenzoquat ion, diflumetorim, dimethomorph,
dimoxystrobin, diniconazole, diniconazole-M, dinobuton, dinocap,
diphenylamine, dithianon, dodemorph, dodemorph acetate, dodine,
dodine free base, edifenphos, enestrobin, epoxiconazole, ethaboxam,
ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol,
fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil,
fenpropidin, fenpropimorph, fenpyrazamine, fentin, fentin acetate,
fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil,
flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin,
fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil,
flutriafol, fluxapyroxad, folpet, formaldehyde, fosetyl,
fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, guazatine,
guazatine acetates, GY-81, hexachlorobenzene, hexaconazole,
hymexazol, imazalil, imazalil sulfate, imibenconazole,
iminoctadine, iminoctadine triacetate, iminoctadine
tris(albesilate), iodocarb, ipconazole, ipfenpyrazolone,
iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam,
isotianil, laminarin, kasugamycin, kasugamycin hydrochloride
hydrate, kresoxim-methyl, mancopper, mancozeb, mandipropamid,
maneb, mefenoxam, mepanipyrim, mepronil, meptyl-dinocap, mercuric
chloride, mercuric oxide, mercurous chloride, metalaxyl,
metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium,
metconazole, methasulfocarb, methyl iodide, methyl isothiocyanate,
metiram, metominostrobin, metrafenone, mildiomycin, myclobutanil,
nabam, nitrothal-isopropyl, nuarimol, octhilinone, ofurace, oleic
acid (fatty acids), orysastrobin, oxadixyl, oxine-copper,
oxpoconazole fumarate, oxycarboxin, pefurazoate, penconazole,
pencycuron, penflufen, pentachlorophenol, pentachlorophenyl
laurate, penthiopyrad, phenylmercury acetate, phosphonic acid,
phthalide, picoxystrobin, polyoxin B, polyoxins, polyoxorim,
potassium bicarbonate, potassium hydroxyquinoline sulfate,
probenazole, prochloraz, procymidone, propamocarb, propamocarb
hydrochloride, propiconazole, propineb, proquinazid,
prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin,
pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil,
pyriofenone, pyroquilon, quinoclamine, quinoxyfen, quintozene,
Reynoutria sachalinensis extract, sedaxane, silthiofam,
simeconazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium
pentachlorophenoxide, spiroxamine, sulfur, SYP-Z071, SYP-Z048, tar
oils, tebuconazole, tebufloquin, tecnazene, tetraconazole,
thiabendazole, thifluzamide, thiophanate-methyl, thiram, tiadinil,
tolclofos-methyl, tolylfluanid, triadimefon, triadimenol,
triazoxide, tricyclazole, tridemorph, trifloxystrobin,
triflumizole, triforine, triticonazole, validamycin, valifenalate,
valiphenal, vinclozolin, zineb, ziram, zoxamide, Candida oleophila,
Fusarium oxysporum, Gliocladium spp., Phlebiopsis gigantea,
Streptomyces griseoviridis, Trichoderma spp.,
(RS)--N-(3,5-dichlorophenyl)-2-(methoxymethyl)-succinimide,
1,2-dichloropropane, 1,3-dichloro-1,1,3,3-tetrafluoroacetone
hydrate, 1-chloro-2,4-dinitronaphthalene, 1-chloro-2-nitropropane,
2-(2-heptadecyl-2-imidazolin-1-yl)ethanol,
2,3-dihydro-5-phenyl-1,4-dithi-ine 1,1,4,4-tetraoxide,
2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride,
2-methoxyethylmercury silicate,
3-(4-chlorophenyl)-5-methylrhodanine, 4-(2-nitroprop-1-enyl)phenyl
thiocyanateme, ampropylfos, anilazine, azithiram, barium
polysulfide, Bayer 32394, benodanil, benquinox, bentaluron,
benzamacril; benzamacril-isobutyl, benzamorf, binapacryl,
bis(methylmercury) sulfate, bis(tributyltin) oxide, buthiobate,
cadmium calcium copper zinc chromate sulfate, carbamorph, CECA,
chlobenthiazone, chloraniformethan, chlorfenazole, chlorquinox,
climbazole, cyclafuramid, cypendazole, cyprofuram, decafentin,
dichlone, dichlozoline, diclobutrazol, dimethirimol, dinocton,
dinosulfon, dinoterbon, dipyrithione, ditalimfos, dodicin,
drazoxolon, EBP, ESBP, etaconazole, etem, ethirim, fenaminosulf,
fenapanil, fenitropan, fluotrimazole, furcarbanil, furconazole,
furconazole-cis, furmecyclox, furophanate, glyodine, griseofulvin,
halacrinate, Hercules 3944, hexylthiofos, ICIA0858, isopamphos,
isovaledione, mebenil, mecarbinzid, metazoxolon, methfuroxam,
methylmercury dicyandiamide, metsulfovax, milneb, mucochloric
anhydride, myclozolin, N-3,5-dichlorophenyl-succinimide,
N-3-nitrophenylitaconimide, natamycin,
N-ethylmercurio-4-toluenesulfonanilide, nickel
bis(dimethyldithiocarbamate), OCH, phenylmercury
dimethyldithiocarbamate, phenylmercury nitrate, phosdiphen,
picolinamide UK-2A and derivatives thereof, prothiocarb;
prothiocarb hydrochloride, pyracarbolid, pyridinitril, pyroxychlor,
pyroxyfur, quinacetol, quinacetol sulfate, quinazamid,
quinconazole, rabenzazole, salicylanilide, SSF-109, sultropen,
tecoram, thiadifluor, thicyofen, thiochlorfenphim, thiophanate,
thioquinox, tioxymid, triamiphos, triarimol, triazbutil,
trichlamide, urbacid, and zarilamide, and any combinations
thereof.
[0167] Additionally, the compounds of the present invention may be
combined with other pesticides, including insecticides,
nematocides, miticides, arthropodicides, bactericides or
combinations thereof that are compatible with the compounds of the
present invention in the medium selected for application, and not
antagonistic to the activity of the present compounds to form
pesticidal mixtures and synergistic mixtures thereof. The
fungicidal compounds of the present disclosure may be applied in
conjunction with one or more other pesticides to control a wider
variety of undesirable pests. When used in conjunction with other
pesticides, the presently claimed compounds may be formulated with
the other pesticide(s), tank mixed with the other pesticide(s) or
applied sequentially with the other pesticide(s). Typical
insecticides include, but are not limited to: 1,2-dichloropropane,
abamectin, acephate, acetamiprid, acethion, acetoprole,
acrinathrin, acrylonitrile, alanycarb, aldicarb, aldoxycarb,
aldrin, allethrin, allosamidin, allyxycarb, alpha-cypermethrin,
alpha-ecdysone, alpha-endosulfan, amidithion, aminocarb, amiton,
amiton oxalate, amitraz, anabasine, athidathion, azadirachtin,
azamethiphos, azinphos-ethyl, azinphos-methyl, azothoate, barium
hexafluorosilicate, barthrin, bendiocarb, benfuracarb, bensultap,
beta-cyfluthrin, beta-cypermethrin, bifenthrin, bioallethrin,
bioethanomethrin, biopermethrin, bistrifluron, borax, boric acid,
bromfenvinfos, bromocyclen, bromo-DDT, bromophos, bromophos-ethyl,
bufencarb, buprofezin, butacarb, butathiofos, butocarboxim,
butonate, butoxycarboxim, cadusafos, calcium arsenate, calcium
polysulfide, camphechlor, carbanolate, carbaryl, carbofuran, carbon
disulfide, carbon tetrachloride, carbophenothion, carbosulfan,
cartap, cartap hydrochloride, chlorantraniliprole, chlorbicyclen,
chlordane, chlordecone, chlordimeform, chlordimeform hydrochloride,
chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron,
chlormephos, chloroform, chloropicrin, chlorphoxim, chlorprazophos,
chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide,
cinerin I, cinerin II, cinerins, cismethrin, cloethocarb,
closantel, clothianidin, copper acetoarsenite, copper arsenate,
copper naphthenate, copper oleate, coumaphos, coumithoate,
crotamiton, crotoxyphos, crufomate, cryolite, cyanofenphos,
cyanophos, cyanthoate, cyantraniliprole, cyclethrin, cycloprothrin,
cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin, cyromazine,
cythioate, DDT, decarbofuran, deltamethrin, demephion, demephion-O,
demephion-S, demeton, demeton-methyl, demeton-O, demeton-O-methyl,
demeton-S, demeton-S-methyl, demeton-S-methylsulphon,
diafenthiuron, dialifos, diatomaceous earth, diazinon, dicapthon,
dichlofenthion, dichlorvos, dicresyl, dicrotophos, dicyclanil,
dieldrin, diflubenzuron, dilor, dimefluthrin, dimefox, dimetan,
dimethoate, dimethrin, dimethylvinphos, dimetilan, dinex,
dinex-diclexine, dinoprop, dinosam, dinotefuran, diofenolan,
dioxabenzofos, dioxacarb, dioxathion, disulfoton, dithicrofos,
d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium,
doramectin, ecdysterone, emamectin, emamectin benzoate, EMPC,
empenthrin, endosulfan, endothion, endrin, EPN, epofenonane,
eprinomectin, esdepallethrine, esfenvalerate, etaphos,
ethiofencarb, ethion, ethiprole, ethoate-methyl, ethoprophos, ethyl
formate, ethyl-DDD, ethylene dibromide, ethylene dichloride,
ethylene oxide, etofenprox, etrimfos, EXD, famphur, fenamiphos,
fenazaflor, fenchlorphos, fenethacarb, fenfluthrin, fenitrothion,
fenobucarb, fenoxacrim, fenoxycarb, fenpirithrin, fenpropathrin,
fensulfothion, fenthion, fenthion-ethyl, fenvalerate, fipronil,
flometoquin, flonicamid, flubendiamide, flucofuron, flucycloxuron,
flucythrinate, flufenerim, flufenoxuron, flufenprox, flufiprole,
flupyradifurone, fluvalinate, fonofos, formetanate, formetanate
hydrochloride, formothion, formparanate, formparanate
hydrochloride, fosmethilan, fospirate, fosthietan, furathiocarb,
furethrin, gamma-cyhalothrin, gamma-HCH, halfenprox, halofenozide,
HCH, HEOD, heptachlor, heptenophos, heterophos, hexaflumuron, HHDN,
hydramethylnon, hydrogen cyanide, hydroprene, hyquincarb,
imidacloprid, imiprothrin, indoxacarb, iodomethane, IPSP, isazofos,
isobenzan, isocarbophos, isodrin, isofenphos, isofenphos-methyl,
isoprocarb, isoprothiolane, isothioate, isoxathion, ivermectin,
jasmolin I, jasmolin II, jodfenphos, juvenile hormone I, juvenile
hormone II, juvenile hormone III, kelevan, kinoprene,
lambda-cyhalothrin, lead arsenate, lepimectin, leptophos, lindane,
lirimfos, lufenuron, lythidathion, malathion, malonoben, mazidox,
mecarbam, mecarphon, menazon, meperfluthrin, mephosfolan, mercurous
chloride, mesulfenfos, metaflumizone, methacrifos, methamidophos,
methidathion, methiocarb, methocrotophos, methomyl, methoprene,
methoxychlor, methoxyfenozide, methyl bromide, methyl
isothiocyanate, methylchloroform, methylene chloride, metofluthrin,
metolcarb, metoxadiazone, mevinphos, mexacarbate, milbemectin,
milbemycin oxime, mipafox, mirex, molosultap, monocrotophos,
monomehypo, monosultap, morphothion, moxidectin, naftalofos, naled,
naphthalene, nicotine, nifluridide, nitenpyram, nithiazine,
nitrilacarb, novaluron, noviflumuron, omethoate, oxamyl,
oxydemeton-methyl, oxydeprofos, oxydisulfoton,
para-dichlorobenzene, parathion, parathion-methyl, penfluron,
pentachlorophenol, permethrin, phenkapton, phenothrin, phenthoate,
phorate, phosalone, phosfolan, phosmet, phosnichlor, phosphamidon,
phosphine, phoxim, phoxim-methyl, pirimetaphos, pirimicarb,
pirimiphos-ethyl, pirimiphos-methyl, potassium arsenite, potassium
thiocyanate, pp'-DDT, prallethrin, precocene I, precocene II,
precocene III, primidophos, profenofos, profluralin, promacyl,
promecarb, propaphos, propetamphos, propoxur, prothidathion,
prothiofos, prothoate, protrifenbute, pyraclofos, pyrafluprole,
pyrazophos, pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins,
pyridaben, pyridalyl, pyridaphenthion, pyrifluquinazon,
pyrimidifen, pyrimitate, pyriprole, pyriproxyfen, quassia,
quinalphos, quinalphos-methyl, quinothion, rafoxanide, resmethrin,
rotenone, ryania, sabadilla, schradan, selamectin, silafluofen,
silica gel, sodium arsenite, sodium fluoride, sodium
hexafluorosilicate, sodium thiocyanate, sophamide, spinetoram,
spinosad, spiromesifen, spirotetramat, sulcofuron,
sulcofuron-sodium, sulfluramid, sulfotep, sulfoxaflor, sulfuryl
fluoride, sulprofos, tau-fluvalinate, tazimcarb, TDE, tebufenozide,
tebufenpyrad, tebupirimfos, teflubenzuron, tefluthrin, temephos,
TEPP, terallethrin, terbufos, tetrachloroethane, tetrachlorvinphos,
tetramethrin, tetramethylfluthrin, theta-cypermethrin, thiacloprid,
thiamethoxam, thicrofos, thiocarboxime, thiocyclam, thiocyclam
oxalate, thiodicarb, thiofanox, thiometon, thiosultap,
thiosultap-disodium, thiosultap-monosodium, thuringiensin,
tolfenpyrad, tralomethrin, transfluthrin, transpermethrin,
triarathene, triazamate, triazophos, trichlorfon,
trichlormetaphos-3, trichloronat, trifenofos, triflumuron,
trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb,
zeta-cypermethrin, zolaprofos, and any combinations thereof.
[0168] Additionally, the compounds of the present invention may be
combined with herbicides that are compatible with the compounds of
the present invention in the medium selected for application, and
not antagonistic to the activity of the present compounds to form
pesticidal mixtures and synergistic mixtures thereof. The
fungicidal compounds of the present disclosure may be applied in
conjunction with one or more herbicides to control a wide variety
of undesirable plants. When used in conjunction with herbicides,
the presently claimed compounds may be formulated with the
herbicide(s), tank mixed with the herbicide(s) or applied
sequentially with the herbicide(s). Typical herbicides include, but
are not limited to: 4-CPA; 4-CPB; 4-CPP; 2,4-D; 3,4-DA; 2,4-DB;
3,4-DB; 2,4-DEB; 2,4-DEP; 3,4-DP; 2,3,6-TBA; 2,4,5-T; 2,4,5-TB;
acetochlor, acifluorfen, aclonifen, acrolein, alachlor,
allidochlor, alloxydim, allyl alcohol, alorac, ametridione,
ametryn, amibuzin, amicarbazone, amidosulfuron,
aminocyclopyrachlor, aminopyralid, amiprofos-methyl, amitrole,
ammonium sulfamate, anilofos, anisuron, asulam, atraton, atrazine,
azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid,
benazolin, bencarbazone, benfluralin, benfuresate, bensulfuron,
bensulide, bentazone, benzadox, benzfendizone, benzipram,
benzobicyclon, benzofenap, benzofluor, benzoylprop, benzthiazuron,
bicyclopyrone, bifenox, bilanafos, bispyribac, borax, bromacil,
bromobonil, bromobutide, bromofenoxim, bromoxynil, brompyrazon,
butachlor, butafenacil, butamifos, butenachlor, buthidazole,
buthiuron, butralin, butroxydim, buturon, butylate, cacodylic acid,
cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor,
carbasulam, carbetamide, carboxazole chlorprocarb, carfentrazone,
CDEA, CEPC, chlomethoxyfen, chloramben, chloranocryl, chlorazifop,
chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac,
chlorfenprop, chlorflurazole, chlorflurenol, chloridazon,
chlorimuron, chlornitrofen, chloropon, chlorotoluron, chloroxuron,
chloroxynil, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid,
cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim,
cliodinate, clodinafop, clofop, clomazone, clomeprop, cloprop,
cloproxydim, clopyralid, cloransulam, CMA, copper sulfate, CPMF,
CPPC, credazine, cresol, cumyluron, cyanatryn, cyanazine, cycloate,
cyclosulfamuron, cycloxydim, cycluron, cyhalofop, cyperquat,
cyprazine, cyprazole, cypromid, daimuron, dalapon, dazomet,
delachlor, desmedipham, desmetryn, di-allate, dicamba, dichlobenil,
dichloralurea, dichlormate, dichlorprop, dichlorprop-P, diclofop,
diclosulam, diethamquat, diethatyl, difenopenten, difenoxuron,
difenzoquat, diflufenican, diflufenzopyr, dimefuron, dimepiperate,
dimethachlor, dimethametryn, dimethenamid, dimethenamid-P,
dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam,
dinoseb, dinoterb, diphenamid, dipropetryn, diquat, disul,
dithiopyr, diuron, DMPA, DNOC, DSMA, EBEP, eglinazine, endothal,
epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethametsulfuron,
ethidimuron, ethiolate, ethofumesate, ethoxyfen, ethoxysulfuron,
etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop,
fenoxaprop, fenoxaprop-P, fenoxasulfone, fenteracol, fenthiaprop,
fentrazamide, fenuron, ferrous sulfate, flamprop, flamprop-M,
flazasulfuron, florasulam, fluazifop, fluazifop-P, fluazolate,
flucarbazone, flucetosulfuron, fluchloralin, flufenacet,
flufenican, flufenpyr, flumetsulam, flumezin, flumiclorac,
flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen,
fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil,
flupropanate, flupyrsulfuron, fluridone, flurochloridone,
fluroxypyr, flurtamone, fluthiacet, fomesafen, foramsulfuron,
fosamine, furyloxyfen, glufosinate, glufosinate-P, glyphosate,
halosafen, halosulfuron, haloxydine, haloxyfop, haloxyfop-P,
hexachloroacetone, hexaflurate, hexazinone, imazamethabenz,
imazamox, imazapic, imazapyr, imazaquin, imazethapyr,
imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane,
iodosulfuron, iofensulfuron, ioxynil, ipazine, ipfencarbazone,
iprymidam, isocarbamid, isocil, isomethiozin, isonoruron,
isopolinate, isopropalin, isoproturon, isouron, isoxaben,
isoxachlortole, isoxaflutole, isoxapyrifop, karbutilate,
ketospiradox, lactofen, lenacil, linuron, MAA, MAMA, MCPA,
MCPA-thioethyl, MCPB, mecoprop, mecoprop-P, medinoterb, mefenacet,
mefluidide, mesoprazine, mesosulfuron, mesotrione, metam,
metamifop, metamitron, metazachlor, metazosulfuron, metflurazon,
methabenzthiazuron, methalpropalin, methazole, methiobencarb,
methiozolin, methiuron, methometon, methoprotryne, methyl bromide,
methyl isothiocyanate, methyldymron, metobenzuron, metobromuron,
metolachlor, metosulam, metoxuron, metribuzin, metsulfuron,
molinate, monalide, monisouron, monochloroacetic acid, monolinuron,
monuron, morfamquat, MSMA, naproanilide, napropamide, naptalam,
neburon, nicosulfuron, nipyraclofen, nitralin, nitrofen,
nitrofluorfen, norflurazon, noruron, OCH, orbencarb,
ortho-dichlorobenzene, orthosulfamuron, oryzalin, oxadiargyl,
oxadiazon, oxapyrazon, oxasulfuron, oxaziclomefone, oxyfluorfen,
parafluron, paraquat, pebulate, pelargonic acid, pendimethalin,
penoxsulam, pentachlorophenol, pentanochlor, pentoxazone,
perfluidone, pethoxamid, phenisopham, phenmedipham,
phenmedipham-ethyl, phenobenzuron, phenylmercury acetate, picloram,
picolinafen, pinoxaden, piperophos, potassium arsenite, potassium
azide, potassium cyanate, pretilachlor, primisulfuron, procyazine,
prodiamine, profluazol, profluralin, profoxydim, proglinazine,
prometon, prometryn, propachlor, propanil, propaquizafop,
propazine, propham, propisochlor, propoxycarbazone,
propyrisulfuron, propyzamide, prosulfalin, prosulfocarb,
prosulfuron, proxan, prynachlor, pydanon, pyraclonil, pyraflufen,
pyrasulfotole, pyrazolynate, pyrazosulfuron, pyrazoxyfen,
pyribenzoxim, pyributicarb, pyriclor, pyridafol, pyridate,
pyriftalid, pyriminobac, pyrimisulfan, pyrithiobac, pyroxasulfone,
pyroxsulam, quinclorac, quinmerac, quinoclamine, quinonamid,
quizalofop, quizalofop-P, rhodethanil, rimsulfuron, saflufenacil,
S-metolachlor, sebuthylazine, secbumeton, sethoxydim, siduron,
simazine, simeton, simetryn, SMA, sodium arsenite, sodium azide,
sodium chlorate, sulcotrione, sulfallate, sulfentrazone,
sulfometuron, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA,
tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim,
terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine,
terbutryn, tetrafluron, thenylchlor, thiazafluron, thiazopyr,
thidiazimin, thidiazuron, thiencarbazone-methyl, thifensulfuron,
thiobencarb, tiocarbazil, tioclorim, topramezone, tralkoxydim,
triafamone, tri-allate, triasulfuron, triaziflam, tribenuron,
tricamba, triclopyr, tridiphane, trietazine, trifloxysulfuron,
trifluralin, triflusulfuron, trifop, trifopsime,
trihydroxytriazine, trimeturon, tripropindan, tritac tritosulfuron,
vernolate, and xylachlor.
[0169] Another embodiment of the present disclosure is a method for
the control or prevention of fungal attack. This method comprises
applying to the soil, plant, roots, foliage, seed or locus of the
fungus, or to a locus in which the infestation is to be prevented
(for example applying to cereal plants), a fungicidally effective
amount of one or more of the compounds of Formula I. The compounds
are suitable for treatment of various plants at fungicidal levels,
while exhibiting low phytotoxicity. The compounds may be useful
both in a protectant and/or an eradicant fashion.
[0170] The compounds have been found to have significant fungicidal
effect particularly for agricultural use. Many of the compounds are
particularly effective for use with agricultural crops and
horticultural plants. Additional benefits may include, but are not
limited to, improving the health of a plant; improving the yield of
a plant (e.g. increased biomass and/or increased content of
valuable ingredients); improving the vigor of a plant (e.g.
improved plant growth and/or greener leaves); improving the quality
of a plant (e.g. improved content or composition of certain
ingredients); and improving the tolerance to abiotic and/or biotic
stress of the plant.
[0171] The compositions of Forumla I may be effective against
pathogen induced diseases where the plant fungal pathogen belonging
to at least one genera selected from Blumeria, Podosphaera,
Sphaerotheca, Uncinula, Erysiphe, Puccinia, Phakopsora,
Gymnosporangium, Hemileia, Uromyces, Alternaria, Cercospora,
Cladosporium, Cochliobolus, Colletotrichum, Magnaporthe,
Mycosphaerella, Phaeosphaeria, Pyrenophora, Ramularia,
Rhyncosporium, Septoria, Venturia, Ustilago, Aspergillus,
Penicillium, Drechslera, Fusarium, Botrytis, Gibberella,
Rhizoctonia, Pseudocercosporella, Sclerotinia, Helminthosporium,
Stagonospora, Exserohilum, and Pyricularia. Pathogens such as
Venturia inaequalis, Septoria tritici, Cercospora beticola,
Cercospora arachidicola, Colletotrichum lagenarium, Puccinia
graminis f. sp. tritici, Uncinula necator, Blumeria graminis, and
Mycosphaerella fijiensis by be controlled by compositions of
Formula I. Additionally, the compositions of Formula I may be
effective in preventing or controlling diseases including apple
scab, speckled leaf blotch of wheat, leaf spot of sugarbeets, leaf
spot of peanut, cucumber anthracnose, wheat leaf rust, grape
powdery mildew, wheat powdery mildew, and black sigatoka.
[0172] The invention provides kits for the treatment or prevention
of agricultural or plant disease or disorders. In one embodiment,
the kit includes a composition containing an effective amount of a
compound herein in a form suitable for delivery to a site plant. In
some embodiments, the kit comprises a container which contains a
compound as described herein (e.g., of any formulae herein); such
containers can be boxes, ampules, bottles, vials, tubes, bags,
pouches, blister-packs, or other suitable container forms known in
the art. Such containers can be made of plastic, glass, laminated
paper, metal foil, or other materials suitable for holding
compounds.
[0173] If desired the compound(s) of the invention is provided
together with instructions for administering it to a plant, field,
or other agricultural area. The instructions will generally include
information about the use of the composition for the treatment or
prevention of a metalloenzyme-mediated agricultural disease or
disorder. In other embodiments, the instructions include at least
one of the following: description of the compound; dosage schedule
and administration for treatment or prevention of a
metalloenzyme-mediated agricultural disease or disorder;
precautions; warnings; description of research studies; and/or
references. The instructions may be printed directly on the
container (when present), or as a label applied to the container,
or as a separate sheet, pamphlet, card, or folder supplied in or
with the container.
[0174] The compounds of the present disclosure may be effective in
use with plants in a disease-inhibiting and phytologically
acceptable amount. The term "disease-inhibiting and phytologically
acceptable amount" refers to an amount of a compound that kills or
inhibits the plant disease for which control is desired, but is not
significantly toxic to the plant. This amount will generally be
from about 0.1 to about 1000 ppm (parts per million), with 1 to 500
ppm being preferred. The exact amount of a compound required varies
with the fungal disease to be controlled, the type of formulation
employed, the method of application, the particular plant species,
climate conditions, and the like. A suitable application rate is
typically in the range from about 0.10 to about 4 pounds/acre
(about 0.01 to 0.45 grams per square meter, g/m.sup.2).
[0175] Any range or desired value given herein may be extended or
altered without losing the effects sought, as is apparent to the
skilled person for an understanding of the teachings herein.
EXAMPLES
[0176] The present invention will now be demonstrated using
specific examples that are not to be construed as limiting.
General Experimental Procedures
[0177] Definitions of variables in the structures in schemes herein
are commensurate with those of corresponding positions in the
formulae delineated herein.
Synthesis of Tetrazole Targets
Example 1
Preparation of 4-((6-bromopyridin-3-yl)oxy)benzonitrile (C1)
##STR00004##
[0179] To a solution of 6-bromopyridin-3-ol (10 g, 57.80 mmol) in
DMF (60 mL) was added 4-fluorobenzonitrile (6.99 g, 57.8 mmol) and
K.sub.2CO.sub.3 (11.9 g, 86.70 mmol) and the reaction mixture was
stirred at 80.degree. C. for 16 hours (h). The reaction mixture was
poured into ice water and extracted with ethyl acetate. The organic
layer was dried over sodium sulphate and concentrated. The crude
product was purified by column chromatography (silica gel, 100-200
mesh) to obtain the title compound as an off-white solid (10 g,
63%): mp 113.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.22 (d, J=2.9 Hz, 1H), 7.70-7.63 (m, 2H), 7.56-7.51 (m, 1H), 7.28
(dd, J=8.5, 2.9 Hz, 1H), 7.10-7.02 (m, 2H); EIMS m/z 275.
Example 2
Preparation of ethyl
2-(5-(4-cyanophenoxy)pyridin-2-yl)-2,2-difluoroacetate (C2)
##STR00005##
[0181] A mixture of ethyl 2-bromo-2,2-difluoroacetate (22.13 mL,
109.05 mmol) and copper (13.85 g, 218.1 mmol) in dry
dimethylsulfoxide (DMSO) (80 mL) was stirred at room temperature
(rt) for 4 h. 4-((6-Bromopyridin-3-yl)oxy)benzonitrile (10 g, 36.35
mmol) was added and the mixture heated at 50.degree. C. for 16 h.
The reaction mixture was cooled to room temperature, diluted with
200 mL of ethyl acetate (EtOAc) and stirred for 10 min. The mixture
was filtered through a plug of Celite.RTM. and the filtrate was
washed with saturated NH.sub.4Cl solution to remove any remaining
copper. The solution was dried (Na.sub.2SO.sub.4) and solvent was
removed under reduced pressure to give the title compound as brown
oil (6.5 g, 56.5%): IR (thin film) 2229, 1767 cm.sup.-1; .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 8.44 (d, J=2.7 Hz, 1H), 7.78 (d,
J=8.7 Hz, 1H), 7.73-7.64 (m, 2H), 7.49 (dd, J=8.6, 2.7 Hz, 1H),
7.16-7.07 (m, 2H), 4.39 (q, J=7.1 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H);
ESIMS m/z 319 ([M+H].sup.+).
Example 3
Preparation of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl)pyridin-3-yl)oxy)be-
nzonitrile (C3)
##STR00006##
[0183] To a solution of 1-bromo-2,4-difluorobenzene (0.724 g, 3.77
mmol) in diethyl ether (Et.sub.2O)(20 mL) under a N.sub.2
atmosphere was added n-BuLi (2.49 mL, 4.03 mmol) at -78.degree. C.
and the reaction mixture was stirred for 45 minutes. Ethyl
2-(5-(4-cyanophenoxy)pyridin-2-yl)-2,2-difluoroacetate (1.00 g, 3.1
mmol) in Et.sub.2O (5 mL) was added dropwise and the reaction was
stirred at the same temperature for 1 h. The reaction mixture was
carefully quenched with 1N HCl until the reaction mixture was
acidic. The reaction mixture was allowed to warm to room
temperature and was extracted with Et.sub.2O. The combined organic
phases were dried (Na.sub.2SO.sub.4) and concentrated to afford the
title compound as yellow solid that was used for the next step
without further purification (1.0 g, 83% crude yield): .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 8.36 (d, J=2.7 Hz, 1H), 8.15-8.02 (m,
1H), 7.86 (d, J=8.7 Hz, 1H), 7.74-7.65 (m, 2H), 7.53 (dd, J=8.6,
2.7 Hz, 1H), 7.16-7.06 (m, 2H), 7.05-6.96 (m, 1H), 6.84 (ddd,
J=10.9, 8.6, 2.4 Hz, 1H); .sup.19F NMR (376 MHz, CDCl.sub.3)
.delta. -99.13 (d, J=13.5 Hz), -100.67 (d, J=14.9 Hz), -101.82 (dd,
J=28.5, 14.2 Hz); ESIMS m/z 387 ([M+1].sup.+).
Example 4
Preparation of
4-((6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-yl)oxy-
)benzonitrile (C4)
##STR00007##
[0185] To a magnetically stirred solution of trimethylsulfoxonium
iodide (6.4 g, 29.42 mmol) in dry THF/DMSO (10:6) was added
potassium tert-butoxide (3.302 g, 29.42 mmol) under a N.sub.2
atmosphere. The reaction mixture was stirred at room temperature
for 1 h and then cooled to 0.degree. C.
4-((6-(2-(2,4-Difluorophenyl)-1,1-difluoro-2oxoethyl)pyridin-3-yl)oxy)ben-
zonitrile (8.737 g, 22.63 mmol) in THF (40 mL) was added slowly to
maintain the temperature below 5.degree. C. The reaction mixture
was maintained at 0.degree. C. for 30 min and saturated sodium
bicarbonate was added to quench the reaction. Brine was added and
the mixture was extracted with Et.sub.2O. The combined organic
phases were diluted with hexanes and washed with brine and water,
dried (Na.sub.2SO.sub.4) and concentrated to give the title
compound as an amber oil (4 g, 44%): .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.46 (d, J=2.7 Hz, 1H), 7.73-7.62 (m, 2H), 7.52
(dd, J=8.6, 0.6 Hz, 1H), 7.48-7.35 (m, 2H), 7.13-7.02 (m, 2H),
6.92-6.80 (m, 1H), 6.75 (ddd, J=10.0, 8.9, 2.5 Hz, 1H), 3.46 (d,
J=5.1 Hz, 1H), 3.03-2.96 (m, 1H); ESIMS m/z 401 ([M+H].sup.+).
Example 5
Preparation of
2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)-5-((5-(trifluoromet-
hyl)pyridin-2-yl)oxy)pyridine (C5)
##STR00008##
[0187] To a magnetically stirred mixture of
6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-ol
(250 mg, 0.836 mmol) (prepared as in WO 2012/177635 A1) and
2-chloro-5-(trifluoromethyl)pyridine (910 mg, 5.01 mmol) in dry
DMSO (10.4 mL) was added cesium carbonate (Cs.sub.2CO.sub.3) (544
mg, 1.671 mmol) in a 20 mL vial under N.sub.2 atmosphere. The
reaction mixture was stirred at 60.degree. C. for 2.5 h, then the
reaction was stopped by allowing it to cool to rt. The reaction was
quenched with H.sub.2O, then extracted Et.sub.2O (3.times.). The
combined organic extracts were washed with H.sub.2O (2.times.) and
brine, dried by passing through a phase separator and volatiles
were removed under rotary evaporation. The resulting residue was
loaded onto a pad of Celite.RTM. and purified by flash
chromatography (SiO.sub.2, 10-30% EtOAc/Hexanes over 10 min) to
yield the title compound as a colorless oil (290 mg, 78%): .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.56 (d, J=2.5 Hz, 1H), 8.44-8.39
(m, 1H), 7.98 (dd, J=8.6, 2.4 Hz, 1H), 7.62 (dd, J=8.6, 2.5 Hz,
1H), 7.59-7.53 (m, 1H), 7.41 (dd, J=14.7, 8.2 Hz, 1H), 7.14 (d,
J=8.6 Hz, 1H), 6.89-6.82 (m, 1H), 6.77 (ddd, J=9.8, 9.0, 2.5 Hz,
1H), 3.47 (d, J=5.0 Hz, 1H), 3.03-2.97 (m, 1H). .sup.19F NMR (376
MHz, CDCl.sub.3) .delta. -61.78 (s, 3F), -106.89 (dd, J=257.7, 8.4
Hz, 1F), -107.48--108.26 (m, 2F), -109.29 (q, J=8.3 Hz, 1F); ESIMS
m/z 446 ([M+H].sup.+).
Example 6
Preparation of
5-chloro-2-((6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-
-3-yl)oxy)pyridine (C6)
##STR00009##
[0189] To a magnetically stirred mixture of
6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-ol
(400 mg, 1.337 mmol) and 5-chloro-2-fluoropyridine (805 .mu.L, 8.02
mmol) in dry DMSO (13.4 mL) was added cesium carbonate (871 mg,
2.67 mmol) in a 20 mL vial under N.sub.2 atmosphere. The reaction
mixture was stirred at 75.degree. C. for 2 h, then rt for 12 h. The
reaction as heated to 75.degree. C. for an additional 30 min then
cooled to rt, diluted with Et.sub.2O and poured into a separatory
funnel containing water. The aqueous layer was extracted with
Et.sub.2O (3.times.) and then the combined organic layers were
washed with 1:1 brine:H.sub.2O (3.times.) then once with brine and
dried by passing through a phase separator. Volatiles were removed
by rotary evaporation and the crude residue was loaded onto a pad
of Celite.RTM. and purified by flash chromatography (SiO.sub.2, 10%
EtOAc/Hexanes for 5 min then ramp to 25% over 8 min-paused gradient
at 25%) to yield the title compound as a colorless oil (91 mg,
16.6%): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.53 (d, J=2.4
Hz, 1H), 8.14-8.07 (m, 1H), 7.72 (dd, J=8.7, 2.7 Hz, 1H), 7.57 (dd,
J=8.6, 2.5 Hz, 1H), 7.52 (dd, J=8.6, 0.6 Hz, 1H), 7.40 (dd, J=14.7,
8.2 Hz, 1H), 7.00 (dd, J=8.6, 0.4 Hz, 1H), 6.88-6.82 (m, 1H), 6.76
(ddd, J=9.9, 9.0, 2.5 Hz, 1H), 3.46 (d, J=5.1 Hz, 1H), 3.03-2.96
(m, 1H); .sup.19F NMR (376 MHz, CDCl.sub.3) .delta. -106.83 (dd,
J=257.5, 8.3 Hz, 1F), -107.38--108.26 (m, 2F), -109.27 (q, J=8.4
Hz, 1F); ESIMS m/z 412 ([M+H].sup.+).
Example 7
Preparation of
6-((6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-yl)oxy-
)nicotinonitrile (C7)
##STR00010##
[0191] To a magnetically stirred mixture of
6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-ol
(500 mg, 1.671 mmol) and 6-fluoronicotinonitrile (224 mg, 1.838
mmol) in dry DMSO (5.570 mL) was added Cs.sub.2CO.sub.3 (653 mg,
2.005 mmol) in a 20 mL vial under N.sub.2 atmosphere. The reaction
mixture was stirred at 25.degree. C. for 16 h. The reaction was
quenched with water and extracted with Et.sub.2O (3.times.). The
combined organic layers were dried by passing through a phase
separator and volatiles were removed under a gentle stream of
N.sub.2. The resulting residue was loaded onto a pad of Celite.RTM.
and purified by flash chromatography (SiO.sub.2, 5-30%
EtOAc/Hexanes over 8 min, 30% for 4 min) to yield the title
compound as a colorless oil (667 mg, 99%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.55 (d, J=2.2 Hz, 1H), 8.44 (dd, J=2.3, 0.7
Hz, 1H), 8.00 (dd, J=8.6, 2.3 Hz, 1H), 7.61 (dd, J=8.6, 2.5 Hz,
1H), 7.57 (dd, J=8.6, 0.7 Hz, 1H), 7.41 (dd, J=14.7, 8.2 Hz, 1H),
7.15 (dd, J=8.6, 0.7 Hz, 1H), 6.89-6.82 (m, 1H), 6.76 (ddd, J=9.8,
8.9, 2.5 Hz, 1H), 3.47 (d, J=4.9 Hz, 1H), 3.02-2.98 (m, 1H);
.sup.19F NMR (376 MHz, CDCl.sub.3) .delta. -106.85 (dd, J=258.0,
8.5 Hz, 1F), -107.45--108.24 (m, 2F), -109.31 (q, J=8.5 Hz, 1F);
ESIMS m/z 402 ([M+H].sup.+).
Example 8
Preparation of
2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)-5-(2,2,2-trifluoroe-
thoxy)pyridine (C8)
##STR00011##
[0193] To a magnetically stirred mixture of
6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-ol
(600 mg, 2.005 mmol) and K.sub.2CO.sub.3 (305 mg, 2.206 mmol) in
acetone (6.76 mL) was added 2,2,2-trifluoroethyl
trifluoromethanesulfonate (558 mg, 2.406 mmol) in a 20 mL vial
under an atmosphere of air. The reaction mixture was stirred at
25.degree. C. for 16 h. As the reaction progressed the reaction
mixture became a cloudy beige suspension. The reaction was quenched
with MeOH (2 mL) and then volatiles were removed under a gentle
stream of N.sub.2. The resulting residue was partitioned with water
and CH.sub.2Cl.sub.2 and the organic layer was removed. The aqueous
layer was washed CH.sub.2Cl.sub.2 (2.times.) and combined organic
layers were dried by passing through a phase separator. Volatiles
were removed under a gentle stream of N.sub.2 and the crude orange
oil was carried on without further purification (779 mg, 97%):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.40 (d, J=2.9 Hz, 1H),
7.46 (d, J=8.7 Hz, 1H), 7.38 (dd, J=14.7, 8.2 Hz, 1H), 7.28 (d,
J=2.9 Hz, 1H), 6.88-6.80 (m, 1H), 6.78-6.71 (m, 1H), 4.44 (q, J=7.9
Hz, 2H), 3.43 (d, J=5.1 Hz, 1H), 3.00-2.95 (m, 1H); .sup.19F NMR
(376 MHz, CDCl.sub.3) .delta. -73.75 (s, 3F), -107.01 (dd, J=257.0,
8.5 Hz, 1F), -107.55--108.43 (m, 2F), -109.41 (q, J=8.5 Hz, 1F).
ESIMS m/z 382 ([M+H].sup.+).
Example 9
Preparation of
5-(2,2-difluorocyclopropoxy)-2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluo-
romethyl)pyridine (C9)
##STR00012##
[0195] To a magnetically stirred mixture of
2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)-5-(vinyloxy)pyridin-
e (227 mg, 0.698 mmol) (prepared as in WO 2012/177635 A1) and
trimethyl(trifluoromethyl)silane (1546 .mu.L, 10.47 mmol) in dry
THF (3034 .mu.l) was added sodium iodide (84 mg, 0.558 mmol) in a
10 mL microwave vial under N.sub.2 atmosphere. The reaction mixture
was stirred at 110.degree. C. for 1 h 20 min Upon completion of the
reaction in the microwave, the reaction was poured into a 1:1
mixture of brine and sat. aq. NaHCO.sub.3 and extracted with EtOAc
(3.times.). The combined organic layers were dried by passing
through a phase separator and volatiles were removed under a gentle
stream of N.sub.2. The brown oil was loaded onto a pad of
Celite.RTM. and purified by flash chromatography (SiO.sub.2, 5-25%
EtOAc/Hexanes over 6 min, 25% for 4 min) to yield the title
compound as a brown oil (215 mg, 82%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.43 (d, J=2.8 Hz, 1H), 7.46 (d, J=8.7 Hz, 1H),
7.42-7.32 (m, 2H), 6.87-6.81 (m, 1H), 6.78-6.71 (m, 1H), 4.19-4.10
(m, 1H), 3.43 (t, J=4.8 Hz, 1H), 3.00-2.94 (m, 1H), 1.91 (dddd,
J=14.4, 9.7, 8.8, 6.5 Hz, 1H), 1.71 (ddd, J=20.2, 9.8, 4.9 Hz, 1H);
.sup.19F NMR (376 MHz, CDCl.sub.3) .delta. -106.42--107.22 (m, 1F),
-107.77 (tdd, J=208.8, 70.6, 8.1 Hz, 2F), -109.34--109.49 (m, 1F),
-131.78 (dd, J=169.8, 1.2 Hz, 1F), -147.38 (dd, J=170.0, 4.6 Hz,
1F); ESIMS m/z 376 ([M+H].sup.+).
Example 10
Preparation of
2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)-5-(2,2,2-trifluoroe-
thyl)pyridine (C10)
##STR00013##
[0196] The title compound was prepared as described in WO
2012/177603 A2.
Example 11
Preparation of
5-((difluoromethoxy)methyl)-2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluor-
omethyl)pyridine (C11)
##STR00014##
[0197] The title compound was prepared as described in WO
2012/177603 A2
Example 12A
Preparation of
4-((6-(3-azido-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxypropyl)pyridi-
n-3-yl)oxy)benzonitrile (C12)
##STR00015##
[0199] A solution of
4-((6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-yl)oxy-
)benzonitrile (3.5 g, 8.74 mmol) and sodium azide (1.705 g, 26.2
mmol) in DMF (43.7 mL) was heated at 50.degree. C. for 17 h. The
reaction was poured into sat. aq. NaHCO.sub.3, and the mixture was
extracted with Et.sub.2O (3.times.). The combined organic phases
were washed with brine, dried (MgSO.sub.4) and concentrated to give
the title compound as a brown oil (3.353 g, 69%).
Example 12B
Preparation of
3-azido-2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-(2,2,2-trifluoroethoxy)p-
yridin-2-yl)propan-2-ol (C16)
##STR00016##
[0201] To a magnetically stirred mixture of
2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)-5-(2,2,2-trifluoroe-
thoxy)pyridine (775 mg, 2.033 mmol) and ammonium chloride (326 mg,
6.10 mmol) in MeOH (6.776 mL) was added sodium azide (396 mg, 6.10
mmol) in a 20 mL vial under a N.sub.2 atmosphere. The reaction
mixture was stirred at 50.degree. C. for 16 h. The reaction was
cooled to rt, then volatiles were removed under a gentle stream of
N.sub.2. Et.sub.2O was added to the resulting residue and stirred
rapidly for 5 min, then filtered to remove solids. The volatiles
were removed by rotary evaporation and the resulting oil was
carried on without further purification.
[0202] Compounds C12-C19 in Table 12a were made in accordance with
the procedures described in Example 12A and Example 12B.
Characterization data for compound C12-C19 is shown in Table
12b.
##STR00017##
TABLE-US-00001 TABLE 12a Compound No. R Appearance Method C12
##STR00018## brown oil 12A C13 ##STR00019## light brown oil 12B C14
##STR00020## light yellow oil 12B C15 ##STR00021## light brown oil
12B C16 ##STR00022## orange oil 12B C17 ##STR00023## orange oil 12B
C18 ##STR00024## yellow oil 12B C19 ##STR00025## light yellow oil
12B
TABLE-US-00002 TABLE 12b Com- pound Mp ESIMS .sup.13C NMR or No.
(.degree. C.) m/z .sup.1H NMR (.delta.) .sup.19F NMR (.delta.) C12
444 .sup.1H NMR (300 MHz, ([M + CDCl.sub.3) .delta. 8.43 (m, 1H),
H].sup.+) 7.67 (m, 3H), 7.57 (d, J = 8.7 Hz, 1H), 7.43 (dd, J =
8.7, 2.7 Hz, 1H), 7.09 (m, 2H), 6.82 (m, 2H), 6.20 (s, 1H), 4.11
(m, 1H), 3.94 (dd, J = 12.9, 2.3 Hz, 1H) C13 488 .sup.1H NMR (400
MHz, .sup.19F NMR (376 MHz, ([M + CDCl.sub.3) .delta. 8.55 (s, 1H),
CDCl.sub.3) .delta. -61.81 (s, H].sup.+) 8.42 (s, 1H), 8.01 (d, J =
3F), -105.61--105.99 8.4 Hz, 1H), 7.73-7.54 (m, 1F), -106.76 (dd,
(m, 3H), 7.17 (d, J = 8.5 J = 262.5, 23.4 Hz, Hz, 1H), 6.91-6.75
(m, 1F), -108.40 (dd, J = 2H), 6.51 (s, 1H), 4.13 (d, 262.8, 20.0
Hz, 1F), J = 12.5 Hz, 1H), 3.92 (d, -109.66 (d, J = 9.1 Hz, J =
12.6 Hz, 1H) 1F) C14 454 .sup.1H NMR (400 MHz, .sup.19F NMR (376
MHz, ([M + CDCl.sub.3) .delta. 8.52 (d, J = 2.4 CDCl.sub.3) .delta.
-105.84 H].sup.+) Hz, 1H), 8.11 (d, J = 2.6 (ddd, J = 23.4, 20.4,
452 Hz, 1H), 7.74 (dd, J = 8.7, 9.1 Hz, 1F), -106.61 ([M - 2.6 Hz,
1H), 7.72-7.62 (dd, J = 262.7, 23.6 H.sup.-]) (m, 2H), 7.60 (d, J =
8.6 Hz, 1F), -108.29 (dd, Hz, 1H), 7.02 (d, J = 8.7 J = 262.8, 20.2
Hz, Hz, 1H), 6.89-6.77 (m, 1F), -109.74 (d, J = 2H), 6.61 (s, 1H),
4.12 (d, 9.1 Hz, 1F) J = 12.9 Hz, 1H), 3.90 (dd, J = 12.8, 2.0 Hz,
1H) C15 445 .sup.1H NMR (400 MHz, .sup.19F NMR (376 MHz, ([M +
CDCl.sub.3) .delta. 8.54 (d, J = 2.4 CDCl.sub.3) .delta. -105.80
H].sup.+) Hz, 1H), 8.44 (dd, J = 2.3, (ddd, J = 23.3, 19.9, 443 0.7
Hz, 1H), 8.02 (dd, J = 9.2 Hz, 1F), -106.84 ([M - 8.6, 2.3 Hz, 1H),
7.70- (dd, J = 262.5, 23.5 H.sup.-]) 7.62 (m, 3H), 7.17 (dd, Hz,
1F), -108.53 (dd, J = 8.6, 0.7 Hz, 1H), 6.89- J = 262.6, 19.8 Hz,
6.77 (m, 3H), 4.13 (d, J = 1F), -109.53 (d, J = 12.8 Hz, 1H), 3.93
(dd, 9.2 Hz, 1F) J = 12.9, 2.0 Hz, 1H) C16 425 .sup.1H NMR (400
MHz, .sup.19F NMR (376 MHz, ([M + CDCl.sub.3) .delta. 8.37 (d, J =
2.8 CDCl.sub.3) .delta. -73.68 (s, H].sup.+) Hz, 1H), 7.62 (td, J =
8.9, 3F), -105.72--105.91 423 6.6 Hz, 1H), 7.53 (d, J = (m, 1F),
-107.50 (dd, ([M - 8.7 Hz, 1H), 7.33 (dd, J = 61.3, 22.0 Hz,
H.sup.-]) J = 8.8, 2.9 Hz, 1H), 6.87- 2F), -109.63 (d, J = 6.75 (m,
2H), 6.40 (s, 9.2 Hz, 1F) 1H), 4.45 (q, J = 7.8 Hz, 2H), 4.10 (d, J
= 12.9 Hz, 1H), 3.90 (dd, J = 12.9, 2.3 Hz, 1H) C17 419 .sup.1H NMR
(400 MHz, .sup.19F NMR (376 MHz, ([M + CDCl.sub.3) .delta. 8.39 (d,
J = 2.8 CDCl.sub.3) .delta. -105.74- H].sup.+) Hz, 1H), 7.64 (tdd,
J = -105.96 (m, 1F), 417 8.9, 6.6, 2.2 Hz, 1H), 7.53 -106.61 (ddd,
J = ([M - (ddd, J = 8.8, 1.3, 0.6 Hz, 262.3, 99.1, 24.1 Hz,
H.sup.-]) 1H), 7.40 (dd, J = 8.8, 2.9 1F), -107.97 (ddd, J = Hz,
1H), 6.87-6.76 (m, 261.8, 54.2, 19.9 Hz, 2H), 6.54 (d, J = 6.5 Hz,
1F), -109.75 (dd, J = 1H), 4.19-4.07 (m, 2H), 10.4, 9.3 Hz, 1F),
3.87 (dd, J = 12.8, 2.2 Hz, -131.77 (dd, J = 170.3, 1H), 1.99-1.88
(m, 1H), 2.5 Hz, 1F), -147.29 1.74 (ddd, J = 20.0, 9.8, (dd, J =
170.3, 2.2 4.9 Hz, 1H) Hz, 1F) C18 409 .sup.1H NMR (400 MHz,
.sup.19F NMR (376 MHz, ([M + CDCl.sub.3) .delta. 8.58 (s, 1H),
CDCl.sub.3) .delta. -65.63 (s, H].sup.+) 7.79 (d, J = 6.4 Hz, 1H),
3F), -105.66--105.93 407 7.62 (td, J = 8.8, 6.6 Hz, (m, 1F),
-107.98 (dd, ([M - 1H), 7.57 (d, J = 8.2 Hz, J = 263.1, 24.2 Hz,
H.sup.-]) 1H), 6.87-6.75 (m, 2H), 1F), -108.80--109.60 6.51 (s,
1H), 4.10 (d, J = (m, 2F) 12.9 Hz, 1H), 3.91 (dd, J = 12.8, 2.2 Hz,
1H), 3.52-3.43 (m, 2H) C19 407 .sup.1H NMR (400 MHz, .sup.19F NMR
(376 MHz, ([M + CDCl.sub.3) .delta. 8.63 (s, 1H), CDCl.sub.3)
.delta. -84.94 (s, H].sup.+) 7.83 (dd, J = 8.1, 2.1 Hz, 2F),
-105.61--105.82 405 1H), 7.64 (td, J = 8.9, 6.6 (m, 1F), -108.24
(d, ([M - Hz, 1H), 7.58 (d, J = 8.1 J = 24.6 Hz, 1F), H.sup.-]) Hz,
1H), 6.87-6.67 (m, -108.45 (d, J = 20.2 4H), 6.37 (t, J = 73.0 Hz,
Hz, 1F), -109.63 (d, 2H), 4.99 (s, 2H), 4.10 (d, J = 9.1 Hz, 1F) J
= 12.9 Hz, 1H), 3.89 (dd, J = 12.8, 2.3 Hz, 1H)
Example 13
Preparation of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-tosyl-1H-tetraz-
ol-)propyl)pyridin-3-yl)oxy)benzonitrile (C20)
##STR00026##
[0204] A mixture of
4-((6-(3-azido-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxypropyl)pyridi-
n-3-yl)oxy)benzonitrile (1.700 g, 3.07 mmol) and
4-methylbenzenesulfonyl cyanide (0.834 g, 4.60 mmol) was heated
neat at 100.degree. C. in a vial for 16 h. The reaction was cooled
to room temperature, diluted with CH.sub.2Cl.sub.2 and purified by
silica gel chromatography (0-50% EtOAc/hexanes) to give the title
compound as a faint yellow foam (1.109 g, 57%).
[0205] Compounds C20 and F15-F21 in Table 13a were made in
accordance with the procedures described in Example 13.
Characterization data for compound C20 and F15-F21 is shown in
Table 13b.
##STR00027##
TABLE-US-00003 TABLE 13a Compound No. R Appearance C20 ##STR00028##
faint yellow foam F15 ##STR00029## off white foamy solid F16
##STR00030## white solid F17 ##STR00031## foamy white solid F18
##STR00032## off white foamy solid F19 ##STR00033## light yellow
oil F20 ##STR00034## off white foamy solid F21 ##STR00035## light
yellow sticky foam
TABLE-US-00004 TABLE 13B IR Com- (thin pound Mp ESIMS .sup.13C NMR
or film) No. (.degree. C.) m/z .sup.1H NMR (.delta.) .sup.19F NMR
(.delta.) cm.sup.-1 C20 626 .sup.1H NMR (300 MHz, 3107, ([M +
CDCl.sub.3) .delta. 8.37 (d, J = 2229, H].sup.+) 2.7 Hz, 1H), 7.98
(d, J = 1158 8.4 Hz, 2H), 7.73 (d, J = 8.6 Hz, 1H), 7.68 (m, 2H),
7.51 (m, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.13 (m, 2H), 6.83 (m, 2H),
6.67 (s, 1H), 5.70 (d, J = 13.7 Hz, 1H), 5.58 (d, J = 14.2 Hz, 1H),
2.48 (s, 3H) F15 669 .sup.1H NMR (400 MHz, .sup.19F NMR (376 ([M +
CDCl.sub.3) .delta. 8.52 (s, 1H), MHz, CDCl.sub.3) .delta.
H].sup.+) 8.41 (dd, J = 1.6, 0.8 -61.81 (s, 3F), 667 Hz, 1H),
8.03-7.97 -104.10 (td, J = ([M - (m, 3H), 7.76-7.70 27.5, 9.7 Hz,
1F), H.sup.-]) (m, 2H), 7.45-7.37 -105.45 (dd, J = (m, 3H), 7.16
(d, J = 263.9, 27.3 Hz, 8.6 Hz, 1H), 6.90- 1F), -107.63 (dd, 6.82
(m, 1H), 6.81 (s, J = 264.0, 27.3 1H), 6.76-6.70 (m, Hz, 1F),
-108.62 1H), 5.75 (d, J = 13.5 (d, J = 9.7 Hz, Hz, 1H), 5.65 (d, J
= 1F) 14.7 Hz, 1H), 2.48 (s, 3H) F16 635 .sup.1H NMR (400 MHz,
.sup.19F NMR (376 ([M + CDCl.sub.3) .delta. 8.49 (s, 1H), MHz,
CDCl.sub.3) .delta. H].sup.+) 8.11-8.09 (m, 1H), -104.08 (td, J =
633 8.00 (d, J = 8.4 Hz, 27.7, 9.6 Hz, 1F), ([M - 2H), 7.73 (dd, J
= 8.7, -105.40 (dd, J = H.sup.-]) 2.7 Hz, 1H), 7.69 (d, 263.9, 27.4
Hz, J = 1.6 Hz, 2H), 7.44- 1F), -107.44 (dd, 7.36 (m, 3H), 7.02 J =
264.0, 27.3 (dd, J = 8.7, 0.5 Hz, Hz, 1F), -108.70 1H), 6.90 (s,
1H), 6.89- (d, J = 9.6 Hz, 6.82 (m, 1H), 6.76- 1F) 6.70 (m, 1H),
5.73 (d, J = 13.9 Hz, 1H), 5.64 (d, J = 14.6 Hz, 1H), 2.48 (s, 3H)
F17 626 .sup.1H NMR (400 MHz, .sup.19F NMR (376 ([M + CDCl.sub.3)
.delta. 8.52 (s, 1H), MHz, CDCl.sub.3) .delta. H].sup.+) 8.43 (dd,
J = 2.3, 0.7 -104.13 (td, J = 624 Hz, 1H), 8.03-7.98 27.2, 9.7 Hz),
([M - (m, 3H), 7.75-7.71 -105.25 (dd, J = H.sup.-]) (m, 2H),
7.45-7.38 264.4, 27.4 Hz), (m, 3H), 7.17 (dd, J = -107.93 (dd, J =
8.6, 0.7 Hz, 1H), 6.90- 264.2, 27.5 Hz), 6.83 (m, 1H), 6.76-
-108.51 (d, J = 6.70 (m, 2H), 5.75 (d, 9.8 Hz) J = 13.2 Hz, 1H),
5.64 (d, J = 14.6 Hz, 1H), 2.48 (s, 3H) F18 606 .sup.1H NMR (400
MHz, .sup.19F NMR (376 ([M + CDCl.sub.3) .delta. 8.33 (d, J = MHz,
CDCl.sub.3) .delta. H].sup.+) 2.8 Hz, 1H), 8.00 (d, -73.66 (s, 3F),
604 J = 8.4 Hz, 2H), 7.63 -104.16 (td, J = ([M - (d, J = 8.8 Hz,
1H), 27.7, 9.7 Hz, 1F), H.sup.-]) 7.38 (ddd, J = 12.2, -105.13 (dd,
J = 8.8, 6.5 Hz, 4H), 6.88- 263.3, 28.7 Hz, 6.81 (m, 1H), 6.75-
1F), -107.48 (dd, 6.69 (m, 2H), 5.72 (d, J = 263.4, 26.9 J = 13.4
Hz, 1H), 5.61 Hz, 1F), -108.59 (d, J = 14.1 Hz, 1H), (d, J = 9.7
Hz, 4.46 (q, J = 7.8 Hz, 1F) 2H), 2.48 (s, 3H) F19 600 8.35 (d, J =
2.8 Hz, .sup.19F NMR (376 ([M + 1H), 8.00 (dd, J = 8.4, MHz,
CDCl.sub.3) .delta. H].sup.+) 1.7 Hz, 2H), 7.63 (d, -104.03--104.31
598 J = 8.7 Hz, 1H), 7.46- (m, 1F), -104.96 ([M - 7.35 (m, 4H),
6.88- (ddd, J = 115.3, H.sup.-]) 6.81 (m, 2H), 6.75- 87.8, 27.9 Hz,
6.69 (m, 1H), 5.70 (d, 1F), -107.61 J = 13.6 Hz, 1H), 5.60 (ddd, J
= 263.0, (dd, J = 14.5, 4.5 Hz, 27.7, 7.8 Hz, 1F), 1H), 4.17 (tdd,
J = -108.72 (t, J = 8.8, 4.8, 2.3 Hz, 1H), 9.3 Hz, 1F), 2.48 (s,
3H), 1.98- -131.73 (dd, J = 1.87 (m, 1H), 1.73 170.2, 4.5 Hz, (qd,
J = 9.5, 4.7 Hz, 1F), -147.29 (dt, 1H) J = 123.2, 18.5 Hz, 1F) F20
590 .sup.1H NMR (400 MHz, .sup.19F NMR (376 ([M + CDCl.sub.3)
.delta. 8.55 (s, 1H), MHz, CDCl.sub.3) .delta. H].sup.+) 7.99 (d, J
= 8.4 Hz, -65.61 (s, 3F), 588 2H), 7.83 (d, J = 8.0 -104.17 (td, J
= ([M - Hz, 1H), 7.67 (d, J = 27.3, 9.6 Hz, 1F), H.sup.-]) 8.1 Hz,
1H), 7.45- -106.59 (dd, J = 7.33 (m, 3H), 6.88- 264.6, 27.8 Hz,
6.79 (m, 2H), 6.74- 1F), -108.18- 6.67 (m, 1H), 5.73 (d, -109.05
(m, 2F) J = 13.9 Hz, 1H), 5.61 (d, J = 14.2 Hz, 1H), 3.48 (q, J =
10.4 Hz, 2H), 2.48 (s, 3H) F21 588 .sup.1H NMR (400 MHz, .sup.19F
NMR (376 ([M + CDCl.sub.3) .delta. 8.59 (s, 1H), MHz, CDCl.sub.3)
.delta. H].sup.+) 8.00 (d, J = 8.4 Hz, -84.96 (s, 2F), 586 2H),
7.87 (dd, J = 8.1, -103.95--104.20 ([M - 2.0 Hz, 1H), 7.67 (d, (m,
1F), -106.56 H.sup.-]) J = 8.2 Hz, 1H), 7.38 (dd, J = 264.9, (ddd,
J = 15.5, 9.9, 7.3 29.8 Hz, 1F), Hz, 3H), 7.00 (s, 1H), -107.98
(dd, J = 6.88-6.81 (m, 1H), 264.6, 26.6 Hz, 6.74-6.66 (m, 1H), 1F),
-108.58 (d, 6.37 (t, J = 73.0 Hz, J = 9.7 Hz, 1F) 1H), 5.72 (d, J =
13.5 Hz, 1H), 5.63 (d, J = 14.5 Hz, 1H), 4.99 (s, 2H), 2.48 (s,
3H)
Example 14
Preparation of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihy-
dro-1H-tetrazol-)propyl)pyridin-3-yl)oxy)benzothioamide (F1)
##STR00036##
[0207] To a stirred solution of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-tosyl-1H-tetraz-
ol-)propyl)pyridin-3-yl)oxy)benzonitrile (400 mg, 0.64 mmol) in DMF
(4 mL) was added NaSH (sodium hydrogensulfide) (67 mg, 0.961 mmol)
at 0.degree. C. and the reaction mixture was gradually warmed to
room temperature and stirred for 3 h. The reaction mixture was
quenched with water and extracted with ethyl acetate (2.times.30
mL). The combined organic layer was dried over Na.sub.2SO.sub.4,
concentrated and purified by flash chromatography to afford the
title compound as pale green solid (110 mg, 32%).
Example 15
Preparation of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihy-
dro-1H-tetrazol-)propyl)pyridin-3-yl)oxy)benzonitrile (F2)
##STR00037##
[0209] To a magnetically stirred mixture of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-tosyl-1H-tetraz-
ol-)propyl)pyridin-3-yl)oxy)benzonitrile (325 mg, 0.520 mmol) in
dry DMF (2.081 mL) was added sodium hydrogensulfide (43.8 mg, 0.781
mmol) in 3 equal portions (each portion was added to the reaction
mixture at 0.degree. C., the reaction was then removed from the
cooling bath and stirred for 5 min at rt prior to cooling for the
next addition of sodium hydrogensulfide) in a 20 mL vial under
N.sub.2 atmosphere. After 15 min the reaction was cooled back down
to 0.degree. C., quenched with 5 mL H.sub.2O and extracted with
EtOAc (3.times.). The combined organic layers were dried by passing
through a phase separator and the volatiles were removed under a
gentle stream of air. The resulting residue was loaded onto a pad
of Celite.RTM. and purified by flash chromatography (SiO.sub.2, 50%
acetone/hexanes to 100% acetone over 6 min, then 100% for 10 min)
to yield the title compound as an off-white solid (138 mg,
52.8%).
Example 16
Preparation of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-(methylthio)-1H-
-tetrazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile (F11)
##STR00038##
[0211] To a magnetically stirred mixture of
4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihy-
dro-1H-tetrazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile (100 mg,
0.199 mmol) in dry THF (1990 .mu.L) was added sodium hydride (17.51
mg, 0.438 mmol) in a 10 mL vial under N.sub.2 atmosphere. The
reaction mixture was stirred at 0.degree. C. for 15 min at which
point methyl iodide (12.44 .mu.L, 0.199 mmol) was added via
microsyringe. The reaction was allowed to continue stifling at
0.degree. C. for 1 hour. At this point the reaction was quenched
with water and allowed to stir, then removed from the ice bath and
extracted with CH.sub.2Cl.sub.2 (3.times.). The combined organic
layers were dried by passing through a phase separator and
volatiles were removed under a gentle stream of N.sub.2. The
resulting residue was loaded onto a pad of celite and purified
(SiO.sub.2, 10-35% Ethyl Acetate/Hexanes over 8 min, 35% for 4 min)
to give the title compound as an off white foamy solid (82 mg,
76%).
Example 17
Preparation of
1-(5-bromopyridin-2-yl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(5-(methylt-
hio)-1H-tetrazol-1-yl)propan-2-ol (F6)
##STR00039##
[0213] To a magnetically stifled mixture of
5-(methylthio)-1H-tetrazole (118 mg, 1.017 mmol) and
5-bromo-2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridine
(307 mg, 0.848 mmol) (prepared as described in US2012043101,
Compound F, Scheme 2) in dry DMF (4.239 mL) was added potassium
carbonate (141 mg, 1.017 mmol) in a dry 25 mL vial under N.sub.2
atmosphere. The reaction mixture was stifled at 55.degree. C.
overnight. The reaction mixture was cooled to room temperature and
purified by flash chromatography (SiO.sub.2, 100-200 mesh; eluting
with stepwise gradients of EtOAc in hexanes) to afford the title
compound as an off-white wax (34 mg, 8%).
TABLE-US-00005 TABLE 1 Structures for Example Compounds Prepared as
No. Structure Appearance in Example F1 ##STR00040## Pale Green
Solid 14 F2 ##STR00041## Pale Green Solid 15 F3 ##STR00042## White
Solid 15 F4 ##STR00043## White Solid 15 F5 ##STR00044## White Solid
15 F6 ##STR00045## Off-White Wax 17 F7 ##STR00046## Brown Liquid 16
F8 ##STR00047## Cloudy Colorless Oil 15 F9 ##STR00048## Off White
Solid 15 F10 ##STR00049## White Foamy Solid 15 F11 ##STR00050## Off
White Foamy Solid 16 F12 ##STR00051## Light Yellow Oil 16 F13
##STR00052## Off White Foamy Solid 16 F14 ##STR00053## Off White
Solid 15
TABLE-US-00006 TABLE 2 Analytical Data for Example Compounds in
Table 1 MP NO. (.degree. C.) MS .sup.1H NMR .sup.19F NMR F1 214-
ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (282 MHz, 218 m/z 537
DMSO-d.sub.6) .delta. 9.85 (s, CDCl.sub.3) .delta. -97.68- ([M +
H].sup.+) 1H), 9.50 (s, 1H), -98.16 (m, 1 F), 8.41 (d, J = 1.8 Hz,
-103.32 (d, J = 24.8 1H), 8.06-7.93 (m, Hz, 2F), -105.58- 2H),
7.72-7.52 (m, -105.76 (m, 1F) 3H), 7.37 (td, J = 8.9, 6.9 Hz, 1H),
7.16 (ddd, J = 11.9, 9.4, 2.7 Hz, 1H), 7.13-7.06 (m, 2H), 6.92 (td,
J = 9.2, 2.7 Hz, 1H), 5.31 (d, J = 14.9 Hz, 1H), 4.99 (d, J = 14.8
Hz, 1H) F2 ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (376 MHz, m/z
503 DMSO-d.sub.6) .delta. 6 8.45 (d, DMSO-d.sub.6) .delta. -102.50
([M + H].sup.+), J = 2.6 Hz, 1H), (s, 1F), -108.20 (d, 501
7.94-7.89 (m, 2H), J = 25.3 Hz, 2F), ([M - H.sup.-]) 7.70 (dd, J =
8.7, 2.7 -110.73 (s, 1F) Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.36
(dd, J = 15.8, 8.9 Hz, 1H), 7.24-7.20 (m, 2H), 7.20-7.13 (m, 1H),
6.92 (td, J = 8.4, 2.5 Hz, 1H), 5.32 (d, J = 14.6 Hz, 1H), 4.99 (d,
J = 14.6 Hz, 1H) F3 ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (376
MHz, m/z 504 DMSO-d.sub.6) .delta. 8.69 DMSO-d.sub.6) .delta.
-102.15 ([M + H].sup.+), (dd, J = 2.3, 0.7 Hz, (s, 1F), -107.73
(dd, 502 1H), 8.51 (d, J = 2.7 J = 43.9, 26.2 Hz, ([M - H.sup.-])
Hz, 1H), 8.40 (dd, J = 2F), -110.80 (s, 1F) 8.7, 2.3 Hz, 1H), 7.85
(dd, J = 8.6, 2.7 Hz, 1H), 7.66 (d, J = 8.9 Hz, 1H), 7.40- 7.32 (m,
2H), 7.16 (ddd, J = 11.8, 9.2, 2.4 Hz, 1H), 6.91 (td, J = 8.3, 2.4
Hz, 1H), 5.35 (d, J = 14.7 Hz, 1H), 4.98 (d, J = 14.6 Hz, 1H) F4
ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (376 MHz, m/z 513
DMSO-d.sub.6) .delta. 8.47 (d, DMSO-d.sub.6) .delta. -102.92 ([M +
H].sup.+), J = 2.7 Hz, 1H), (s, 1F), -107.37 (t, 511 8.25 (dd, J =
2.7, 0.6 J = 26.2 Hz, 2F), ([M - H.sup.-]) Hz, 1H), 8.04 (dd, J =
-110.50 (s, 1F) 8.8, 2.7 Hz, 1H), 7.79 (dd, J = 8.6, 2.7 Hz, 1H),
7.62 (d, J = 8.7 Hz, 1H), 7.36 (dd, J = 15.9, 8.8 Hz, 1H),
7.30-7.14 (m, 3H), 6.95 (td, J = 8.4, 2.4 Hz, 1H), 5.28 (d, J =
14.7 Hz, 1H), 5.06 (d, J = 14.7 Hz, 1H) F5 ESIMS .sup.1H NMR (400
MHz, .sup.19F NMR (376 MHz, m/z 484 DMSO-d.sub.6) .delta. 8.36 (d,
DMSO-d.sub.6) .delta. -72.54 ([M + H].sup.+), J = 2.8 Hz, 1H), (s,
3F), -102.24 (s, 482 7.69 (s, 1H), 7.63 1F), -107.31- ([M -
H.sup.-]) (dd, J = 8.8, 2.9 Hz, -107.61 (m, 2F), 1H), 7.55 (d, J =
8.7 -110.94 (s, 1F) Hz, 1H), 7.33 (dd, J = 15.9, 8.9 Hz, 1H), 7.14
(ddd, J = 11.9, 9.2, 2.6 Hz, 1H), 6.88 (td, J = 8.5, 2.5 Hz, 1H),
5.32 (d, J = 14.6 Hz, 1H), 4.99- 4.90 (m, 3H) F6 ESIMS .sup.1H NMR
(400 MHz, 1H-decoupled m/z 478 CDCl.sub.3) .delta. 8.59 (d, J =
.sup.19F NMR (376 MHz, and 480 1.8 Hz, 1H), 7.95 CDCl.sub.3)
.delta. -103.59 ([M + H].sup.+), (dd, J = 8.5, 2.3 Hz, (ddd, J =
40.9, 19.1, 476 and 1H), 7.49 (d, J = 8.3 9.5 Hz), -105.06 (d, 478
Hz, 1H), 7.34 (td, J = J = 19.1 Hz), -105.76 ([M - H.sup.-]) 9.0,
6.5 Hz, 1H), (d, J = 19.1 Hz), 6.81 (ddd, J = 12.0, -108.30 (d, J =
9.5 8.5, 2.5 Hz, 1H), Hz), -109.48 (d, J = 6.76-6.67 (m, 1H), 40.9
Hz), -110.17 (d, 6.60 (s, 1H), 5.32 (d, J = 40.9 Hz) J = 14.3 Hz,
1H), 4.96 (dd, J = 14.4, 0.9 Hz, 1H), 2.75 (s, 3H) F7 ESIMS .sup.1H
NMR (300 MHz, .sup.19F NMR (282 MHz, m/z 531 CDCl.sub.3) .delta.
8.14 (s, CDCl.sub.3) .delta. -103.60- ([M + H].sup.+) 1H),
7.71-7.57 (m, -104.08 (m, 1F), 3H), 7.48 (dd, J = -105.92 (dd, J =
15.3, 8.3 Hz, 1H), 871.2, 25.8 Hz, 1F), 7.39 (d, J = 8.6 Hz,
-105.92 (dd, J = 1H), 7.08 (d, J = 8.6 1407.1, 25.8 Hz, 1F), Hz,
2H), 6.90 (s, -108.50--108.74 1H), 6.84-6.66 (m, (m, 1F) 2H), 5.11
(d, J = 14.6 Hz, 1H), 5.00 (d, J = 14.6 Hz, 1H), 3.20 (q, J = 7.3
Hz, 2H), 1.33 (t, J = 7.3 Hz, 3H) F8 ESIMS .sup.1H NMR (400 MHz,
.sup.19F NMR (376 MHz, m/z 547 DMSO-d.sub.6) .delta. 8.52 (d,
DMSO-d.sub.6) .delta. -60.12 ([M + H].sup.+), J = 2.6 Hz, 1H), (s),
-102.91 (s), 545 8.32 (dd, J = 8.9, 2.4 -107.43 (dd, J = 33.7, ([M
- H.sup.-]) Hz, 1H), 7.87 (dd, J = 24.2 Hz), -110.48 (s) 8.6, 2.7
Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.44-7.32 (m, 2H), 7.18 (ddd, J
= 11.9, 9.2, 2.5 Hz, 2H), 6.96 (td, J = 8.5, 2.5 Hz, 1H), 5.28 (d,
J = 14.5 Hz, 1H), 5.08 (d, J = 14.6 Hz, 1H) F9 ESIMS .sup.1H NMR
(400 MHz, .sup.19F NMR (376 MHz, m/z 466 DMSO-d.sub.6) .delta. 8.58
(d, DMSO-d.sub.6) .delta. -82.69 ([M + H].sup.+), J = 1.7 Hz, 1H),
(s, 2F), -102.90 (s, 464 7.97-7.92 (m, 1H), 1F), -107.62- ([M -
H.sup.-]) 7.60 (d, J = 8.4 Hz, -107.88 (m, 2F), 1H), 7.34 (dd, J =
-110.45 (s, 1F) 15.7, 8.9 Hz, 1H), 7.17 (ddd, J = 12.0, 9.2, 2.6
Hz, 2H), 7.03-6.65 (m, 2H), 5.26 (d, J = 14.6 Hz, 1H), 5.09-5.02
(m, 3H) F10 53- ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (376 MHz,
57 m/z 478 DMSO-d.sub.6) .delta. 8.35 (d, DMSO-d.sub.6) .delta.
-102.54 ([M + H].sup.+), J = 2.7 Hz, 1H), (s, 1F), -107.20 (t, 476
7.64-7.60 (m, 1H), J = 29.8 Hz, 2F), ([M - H.sup.-]) 7.57 (d, J =
8.8 Hz, -110.80 (s, 1F), 1H), 7.51 (s, 1H), -130.38 (dd, J =
7.39-7.31 (m, 1H), 164.7, 5.9 Hz, 1F), 7.18-7.11 (m, 1H), -145.32
(dd, J = 6.90 (tt, J = 8.4, 2.5 164.7, 5.6 Hz, 1F) Hz, 1H), 5.29
(d, J = 14.6 Hz, 1H), 4.98 (d, J = 14.8 Hz, 1H), 4.73 (s, 1H),
2.21- 2.10 (m, 1H), 1.91- 1.81 (m, 1H) F11 ESIMS .sup.1H NMR (400
MHz, .sup.19F NMR (376 MHz, m/z 517 CDCl.sub.3) .delta. 8.20 (d, J
= CDCl.sub.3) .delta. -103.17- ([M + H].sup.+), 2.7 Hz, 1H), 7.75-
-104.11 (m, 2F), 515 7.69 (m, 3H), 7.57 -108.06 (dd, J = ([M -
H.sup.-]) (td, J = 8.8, 6.5 Hz, 269.9, 20.9 Hz, 1F), 1H), 7.46 (dd,
J = -108.51 (d, J = 9.3 8.7, 2.7 Hz, 1H), Hz, 1F) 7.18-7.13 (m,
2H), 7.05 (s, 1H), 6.90- 6.78 (m, 2H), 5.18 (d, J = 14.6 Hz, 1H),
5.05 (d, J = 14.7 Hz, 1H), 2.73 (s, 3H) F12 ESIMS .sup.1H NMR (400
MHz, .sup.19F NMR (376 MHz, m/z 593 CDCl.sub.3) .delta. 8.14 (d, J
= CDCl.sub.3) .delta. -102.88- ([M + H].sup.+), 2.6 Hz, 1H), 7.75-
-103.98 (m, 2F), 591 7.70 (m, 2H), 7.67 -107.75--108.67 (m, ([M -
H.sup.-]) (dd, J = 8.7, 0.5 Hz, 2F) 1H), 7.55 (dt, J = 15.1, 7.6
Hz, 1H), 7.43 (dd, J = 8.7, 2.7 Hz, 1H), 7.36-7.27 (m, 5H),
7.18-7.13 (m, 2H), 7.04 (s, 1H), 6.82 (tdd, J = 11.2, 8.5, 2.6 Hz,
2H), 5.13 (d, J = 14.6 Hz, 1H), 4.95 (d, J = 14.6 Hz, 1H),
4.51-4.42 (m, 2H) F13 ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (376
MHz, m/z 557 CDCl.sub.3) .delta. 8.20 (d, J = CDCl.sub.3) .delta.
-103.05- ([M + H].sup.+), 2.7 Hz, 1H), 7.75- -103.99 (m, 2F), 555
7.68 (m, 3H), 7.58 -108.10 (dd, J = ([M - H.sup.-]) (dd, J = 15.3,
8.8 268.4, 16.6 Hz, 1F), Hz, 1H), 7.46 (dd, J = -108.59 (d, J = 9.3
8.7, 2.7 Hz, 1H), Hz, 1F) 7.18-7.13 (m, 2H), 7.01 (s, 1H), 6.89-
6.78 (m, 2H), 5.22 (d, J = 14.6 Hz, 1H), 5.06 (d, J = 14.6 Hz, 1H),
3.21 (d, J = 7.4 Hz, 2H), 1.22-1.10 (m, 1H), 0.66-0.58 (m, 2H),
0.35-0.29 (m, 2H) F14 ESIMS .sup.1H NMR (400 MHz, .sup.19F NMR (376
MHz, m/z 468 DMSO-d.sub.6) .delta. 8.55 (s, DMSO-d.sub.6) .delta.
-64.34 ([M + H].sup.+), 1H), 7.93 (d, J = 8.5 (s, 3F), -102.51 (s,
466 Hz, 1H), 7.60 (d, J = 1F), -108.22 (t, J = ([M - H.sup.-]) 7.7
Hz, 1H), 7.50 (s, 25.1 Hz, 2F), 1H), 7.33 (dd, J = -110.71 (s, 1F)
15.8, 8.9 Hz, 1H), 7.13 (ddd, J = 11.9, 9.2, 2.6 Hz, 1H), 6.88 (td,
J = 8.5, 2.7 Hz, 1H), 5.75 (s, 1H), 5.30 (d, J = 14.5 Hz, 1H), 5.01
(d, J = 14.5 Hz, 1H), 3.81 (q, J = 11.4 Hz, 2H)
Example 18
Evaluation of Fungicidal Activity: Leaf Blotch of Wheat
(Mycosphaerella graminicola; Anamorph: Septoria tritici; Bayer Code
SEPTTR)
[0214] Technical grades of materials were dissolved in acetone,
which were then mixed with nine volumes of water containing 110 ppm
Triton X-100. The fungicide solutions were applied onto wheat
seedlings using an automated booth sprayer to run-off. All sprayed
plants were allowed to air dry prior to further handling.
[0215] Wheat plants (variety Yuma) were grown from seed in a
greenhouse in 50% mineral soil/50% soil-less Metro mix until the
first leaf was fully emerged, with 7-10 seedlings per pot. These
plants were inoculated with an aqueous spore suspension of Septoria
tritici either prior to or after fungicide treatments. After
inoculation the plants were kept in 100% relative humidity (one day
in a dark dew chamber followed by two to three days in a lighted
dew chamber at 20.degree. C.) to permit spores to germinate and
infect the leaf. The plants were then transferred to a greenhouse
set at 20.degree. C. for disease to develop. When disease symptoms
were fully expressed on the 1.sup.st leaves of untreated plants,
infection levels were assessed on a scale of 0 to 100 percent
disease severity. Percent disease control was calculated using the
ratio of disease severity on treated plants relative to untreated
plants.
Example 19
Evaluation of Fungicidal Activity: Wheat Brown Rust (Puccinia
triticina; Synonym: Puccinia recondita f sp. tritici; Bayer Code
PUCCRT)
[0216] Wheat plants (variety Yuma) were grown from seed in a
greenhouse in 50% mineral soil/50% soil-less Metro mix until the
first leaf was fully emerged, with 7-10 seedlings per pot. These
plants were inoculated with an aqueous spore suspension of Puccinia
triticina either prior to or after fungicide treatments. After
inoculation the plants were kept in a dark dew room at 22.degree.
C. with 100% relative humidity overnight to permit spores to
germinate and infect the leaf. The plants were then transferred to
a greenhouse set at 24.degree. C. for disease to develop. Fungicide
formulation, application and disease assessment followed the
procedures as described in Example 18.
TABLE-US-00007 TABLE 3 Biological Testing Rating Scale Rating Table
for Fungal Pathogens % Control Rating 80-100 A More than 0--Less
than 80 B Not Tested C No activity noticed in this bioassay D
TABLE-US-00008 TABLE 4 Biological Activity--Disease Control at 50
ppm Compound PUCCRT SEPTTR No. 1DP 1DC 1DP 3DC F1 A A A A F2 A C A
A F3 A A A B F4 A A A A F5 A A A A F6 B A D B F7 A A B A F8 A A A A
F9 A A A A F10 A A A A F11 A C A A F12 A C B A F13 A C A A F14 C C
C C
INCORPORATION BY REFERENCE
[0217] The contents of all references (including literature
references, issued patents, published patent applications, and
co-pending patent applications) cited throughout this application
are hereby expressly incorporated herein in their entireties by
reference.
EQUIVALENTS
[0218] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents of the specific embodiments of the invention described
herein. Such equivalents are intended with be encompassed by the
following claims.
* * * * *